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 CHAPTER I 
 
INTRODUCTION 
 
Autoimmune diseases and atopic diseases 
The immunological dysfunctions may result from uncontrolled excessive immune 
responses to either self-antigens (autoimmune diseases) or environmental innocuous 
antigens (atopic diseases). Both autoimmune diseases and atopic diseases are 
manifestations of such hypersensitivity of immune responses: 
 
Autoimmune diseases 
Autoimmune diseases affect 3-5% of the human population (1). Clinical 
manifestations are the damage of specific organs, such as in insulin dependent diabetes 
mellitus (IDDM) and multiple sclerosis (MS) or damage to multiple organs and tissues, 
such as in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), resulting 
from inappropriate immune-mediated inflammation (2).  In this thesis, we tried to using 
gene expression profiling method to study these four human autoimmune diseases: 
IDDM, insulin dependent diabetes also called type I diabetes (formerly known as 
"childhood" or "juvenile" diabetes) is most commonly diagnosed in children and 
adolescents. It is an autoimmune disorder, in which the immune system attacks the self-
beta cells in the islets of the pancreas, thus reducing the insulin production (3, 4). MS, 
multiple sclerosis, is a chronic autoimmune disease that affects the brain and spinal cord 
in which the immune system attacks the myelin (sheath) surrounding nerve cells (5, 6). 
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 RA, rheumatoid arthritis, is a chronic, inflammatory autoimmune disorder in which the 
immune system attacks the self joints. The disease is also systemic in that it often also 
affects the skin, blood vessels, heart, lungs and muscles (7, 8). ERA, early rheumatoid 
arthritis, is a subject of the study in this thesis, which refers to the rheumatoid arthritis 
whose disease duration is less than two years. SLE, system lupus erythematosus, is a 
chronic, potentially fatal autoimmune disease in which the immune system attacks the 
self organs and tissue, resulting in inflammation and tissue damage. SLE can systemically 
affect the body, and most often harms the kidneys (lupus nephritis), heart, joints, skin, 
lungs, blood vessels and nervous system (9, 10). 
The failure of self-tolerance is believed to be the underlying cause of the 
formation of immune responses to self organ or tissues. Self-tolerance can be divided into 
two broad categories: central tolerance (11, 12) and peripheral tolerance (13, 14). In 
central tolerance, autoreactive immature lymphocytes in generative lymphoid organs 
(bone marrow for B cells and thymus for T cells) are typically eliminated by apoptosis 
resulting in clonal deletion or are inactivated. Peripheral tolerance controls the mature 
autoreactive lymphocytes that escape the central tolerance checkpoints and migrate to 
periphery. Basic peripheral self tolerance mechanisms include: clonal deletion of 
autoreactive lymphocytes via apoptosis, lymphocytes anergy due to intrinsic regulation to 
increase the activation threshold of autoreactive lymphocytes to self antigens (15), 
eliminating or reducing antibodies or BCRs or TCRs self reactivity by V(D)J 
recombination or somatic hypermutation, and extrinsic active suppression by T 
regulatory cells (16).  
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 Recently, a new theory has been proposed to explain the origins of autoimmune 
disease by studying the murine model of human IDDM – non obese diabetic (NOD) mice 
(17). It has been recognized for some time that NOD mice are lymphopenic (reduced 
numbers of lymphocytes) compared to other strains.  The model proposes that the host 
recognizes the state of lymphopenia and this drives naïve T cells to undergo homeostatic 
expansion in an attempt to fill the empty space.  Proliferation of naïve T cells is 
dependent upon recognition of antigen and the only antigens in the host in the uninfected 
state are self-antigens.  Therefore, this model proposes that the tendency to correct 
lymphopenia supersedes the need to avoid self-reactivity resulting in the generation of a 
population of self-reactive T cells, which migrate to extra-lymphoid sites and increase the 
susceptibility to autoimmune diseases at these sites. This may explain why lymphopenia 
resulting from immunotherapies may predispose people to autoimmune disease (18), such 
as induction of thyroid autoimmunity in 1/3 of patients with multiple sclerosis after 
lymphocyte depleting therapy (19). Studies of another type I diabetes rodent model, the 
BB (BioBreeding) rat, also suggested that lymphopenia may be an essential factor of 
inducing autoimmunity in this model (20-22). 
Environmental factors may also predispose individuals to develop autoimmune 
disease. Infectious agents can mimic the structure of self-antigens, which may induce 
cross-reactivity of lymphocytes to self-antigens and finally result in autoimmune disease. 
This phenomenon has been observed in a variety of cases, such as relapses in MS are 
often triggered by common viral infections, herpesvirus, influenza, measles, papilloma 
virus and Epstein-Barr Virus which all have genes encoding sequences that mimic those 
found in the major structural proteins of myelin (6); the spirochete Borellia burgdorferi. 
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 shares an antigenic determinant with LFA-1 which is targeted by autoimmune response in 
lyme arthritis (23);  a single antigenic determinant on Epstein-Barr virus is also shared 
with one of the  auto-antigens of SLE (24). The components of infectious 
microorganisms such as lipopolysaccharide (LPS), bacterial DNA may substantially 
improve immune responses to unrelated antigens (1, 25, 26), thus acting as adjuvants to 
augment immune responses and overriding checkpoints that prevent responses to self-
antigens. Adjuvants components of infectious microorganisms such as LPS can 
stimulating the innate immune system to produces inflammatory cytokines and increases 
the activity of antigen-presenting cells by inducing class II MHC and costimulatory 
proteins (27, 28). 
Autoimmune diseases also have an underlying genetic basis that is believed to 
increase disease susceptibility. The genetic predisposition to autoimmune diseases is 
supported by epidemiologic evidence. Studies showed when compared autoimmune 
disease incidence between monozygotic twins, between dizygotic twins, among family 
members, and within the general population, the greatest risk of developing autoimmune 
disease is if one’s monozygotic twin has an autoimmune disease, the second greatest is if 
one’s dizygotic twin has an autoimmune disease, and the person also has an increased 
risk of developing autoimmune disease if his/her first-degree relative is with an 
autoimmune disease (2, 29-31). The genetic predisposition to autoimmune disease can be 
divided into two categories: single-gene defect conferring susceptibility to an 
autoimmune disease and polygenic defects that confer susceptibility to develop an 
autoimmune disease (32). There are examples in both human autoimmune disease and 
animal models of autoimmune disease demonstrating that a single gene defect can induce 
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 autoimmune disease (32).  Examples include mutations of AIRE in human autoimmune 
polyendocrine syndrome (APS-1) (33); induced knockout or spontaneous mutation of 
mouse Foxp3 gene, which exhibits high expression in CD4+CD25+ T regulatory cells, 
leads to systemic autoimmune diseases resulting from absence of CD4+CD25+ T 
regulatory cells (16).  Mutation of FOXP3 is associated with human IPEX syndrome 
(immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome).  
Mutation of Fas or Fasl in lpr/lpr and gld/gld mice results in severe lymphoproliferative 
syndromes, similar mutations are also found in humans with lymphoproliferative 
syndrome (ALPS) (34, 35). 
Single gene defects that result in autoimmune syndromes may be straightforward 
and simple to explain. However, single gene defects leading to human autoimmune 
syndromes are very rare and more and more evidence supports the concept that the major 
autoimmune diseases result from a complex combination of polygenic effects (32, 36). 
Genetic linkage studies of human autoimmune diseases and their murine counterparts 
provide strong support for the existence of multigenic effects that contribute to 
autoimmune disease susceptibility (37-39). Comparative genetic mapping of human 
autoimmune diseases and their murine counterparts suggest that a common set of 
susceptibility loci contribute increased susceptibility to several different autoimmune 
diseases (2, 40, 41). The overlapping loci not only exist within each species but also exist 
between human and murine models when susceptibility loci are placed on the same 
genetic map (1, 2, 37, 38, 40-44). The fact that there are common loci shared by different 
autoimmune diseases is the basic rationale for our study to identify common gene 
expression profiles in autoimmune diseases.  
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 Therefore, the combination of the genetic components, environmental factors and 
stochastic events predispose individuals to autoimmune diseases. The increased number 
of susceptibility alleles may increase the risk and incidence of autoimmune diseases and 
reflect a “threshold liability”. This “threshold liability” model postulates the existence of 
a continuous trait, termed liability, and a threshold value of the liability is corresponding 
to different phenotype states. Individuals whose liability exceeds a given threshold will 
exhibit a certain phenotype, such as a certain disease; those with liability value below the 
threshold exhibit a opposite phenotype, such as lack of the diseases (45). The mechanism 
of “threshold liability” has been reported to contribute to establish susceptibility in a 
variety of diseases such as respiratory diseases, certain types of cancers, and Alzheimer 
disease (46-48). The “threshold liability” model in autoimmune diseases has been 
reviewed by Wandstrat et al (2) (Figure 1-1, Wandstrat et al 2001).  
 
 
Figure 1-1. Threshold liabilities in autoimmune disease. In this model, only individuals located to 
the right of the disease threshold line will develop disease. The x axis represents increasing 
liability to disease, individuals located on the x axis based on the degree of their predisposition to 
disease. An incremental increase in the number of susceptibility alleles progressively increases 
liability of disease, resulting in movement toward the disease threshold at the right on the x axis. 
The disease liability introduced by environmental and stochastic effects is represented by the 
normal distribution curve around the location of individuals with specific degrees of genetic 
predisposition for disease. 
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 Murine models of autoimmune diseases have been widely used to study disease 
pathogenesis. In the study of this thesis, we have used the NOD mouse that is a type I 
diabetes murine model and the NZM2410 mouse that is a model of human systemic lupus 
erythematosus. We have also used the NOD congenic strain NOD.H2h4 mice to perform 
genomic comparisons and the C57BL/6 strain was used as a control strain.  
The NOD strain was originally developed in Japan during selection of a cataract-
prone strain derived from outbreed Jc1: ICR mice. The NOD strain was established as a 
subline by inbreeding of brother-sister mating with increased incidence of spontaneous 
diabetes (49, 50). The incidence of diabetes in NOD mice is 60%-80% in females and 
20%-30% in males, and interestingly, the highest incidence of diabetes occurs when mice 
are maintained in a pathogen free environment but incidence is decreased when mice are 
maintained in a relatively “dirty” environment (51, 52). The underlying mechanism of 
this effect is not clear. However, this phenomenon may reflect that the exposure to 
foreign antigens may help gradually maturing the immune system. Therefore, this 
matured immune system may further protect the host from allergic or autoimmune 
diseases (53). Onset of diabetes generally begins at 12 to 14 weeks of age in female mice 
and is a bit delayed in male mice. Mononuclear infiltration surrounding islets (peri-
insulitis) begins at 3 to 4 weeks of age. Progression and invasion of islets (insulitis) 
proceeds during the following weeks and most mice demonstrate insulitis by 10 weeks of 
age. Marked decreases in pancreatic insulin content occur in females at about 12 weeks 
of age and several weeks later in males (50). The delayed incidence of diabetes in male 
mice may suggest late regulatory events (50). Genetic analysis of NOD mice has 
demonstrated that the phenotype is controlled by loci distributed over at least 11 different 
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 chromosomes and 19 different disease susceptibility loci have been designated (Idd loci, 
refer to insulin-dependent diabetes (41)). Although all of these susceptibility loci 
contribute to development of diabetes of NOD mice, the Idd1 locus confers the greatest 
risk (1, 50, 54-58). Genes within this locus encode major histocompatability complex 
(MHC) proteins of the class II type, I-A and I-E. The NOD haplotype I-Ag7 has been 
intensively studied and confirmed to be the major genetic risk factor for susceptibility of 
diabetes (41, 54, 59, 60). The pathogenesis of diabetes in NOD mice has been studied for 
decades. Several mechanisms, other than genetic predisposition to diseases susceptibility, 
have been proposed such as break of central and peripheral tolerance, defects in 
regulatory systems and recently proposed mechanisms of generation of autoimmunity by 
homeostatic expansion under lymphopenic pressure (50). The evidence identified in 
another diabetes rodent model-BB rat (BioBreeding rat) supports that lymphopenia may 
drive to autoimmunity. The profound lymphodeficiency of the BB rat is demonstrated to 
contribute to diseases pathogenesis (20, 21). However, all these above mechanisms 
contributing to autoimmune diseases may also develop from the genetic background of 
NOD mouse. 
NOD mice have been used as a surrogate for human diabetes for several decades 
and our understanding of pathogenesis of type I diabetes (IDDM, insulin dependent 
diabetes mellitus) is advanced by analyses of this model. However, because of the genus 
difference, limitations of this modeling exist, such as, deafness, the absence of C5 
complement, resistance to ketoacidosis and the absence of the murine homolog of HLA-
DR molecules on antigen-presenting cells in NOD mouse (55). We must realize that this 
highly inbred type I diabetes model can only be viewed as analogous to a single “case 
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 study” in humans. It can not fully model the heterogeneous genetics of human type I 
diabetes.  
Congenic strains of NOD mouse represent a powerful tool to dissect the polygenic 
effects of multiple susceptible loci of type I diabetes. The congenic strains are special 
types of inbred strains in which part of the genome is transferred from another inbred 
strain by backcrossing the donor mouse and recipient mouse with a phenotypic or 
genotypic selection. In this study (see chapter VI: part I), we used a NOD congenic strain, 
NOD.H2h4, which contains I-A regions (Idd1) transferred from B10.H2h4 mouse onto the 
NOD background. Thus, this congenic strain changes the composition of the loci, Idd1, 
that confers the greatest disease liability of NOD mouse and this congenic strain does not 
develop type I diabetes.  
NZM2410 is a model of human systemic lupus erythematosus. It is one of the 
NZM strains originated from crossing NZB and NZW strains (61). This inbred strain 
develops glomerulonephritis by one year of age in ~80% of males and females. Anti-
dsDNA IgG antibodies are also present in the sera of ~80% of animals by six months of 
age. The strain is a valuable tool to investigate autoimmunity and the genetic components 
and pathology of murine systemic lupus erythematosus (SLE). Spontaneous SLE in NZM 
models is characterized by serum autoantibodies to chromatin, double-stranded DNA 
(dsDNA), histone proteins, and other antigens (61). 
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 Atopic diseases 
Atopic diseases are another group of immune-mediated human diseases studied in 
this thesis. They comprise a group of syndromes that include asthma, allergic rhinitis, and 
atopic dermitis. These diseases are caused by allergic response belonging to immediate 
hypersensitivity, which is the pathologic process that results from immunologically 
specific interactions between antigens (exogenous or endogenous) and humoral 
antibodies or sensitized lymphocytes.  Immediate hypersensitivity is an immune reaction 
that is initiated by antigen binding to IgE on mast cells or basophils and leading to release 
of inflammatory mediators. These mediators cause allergic responses such as increased 
vascular permeability, vasodilation, bronchial and visceral smooth muscle contraction, 
and local inflammation. Figure 1-2 shows the cascade of allergic responses. 
 
 
Figure 1-2. Cascade of allergic responses. 
 
This reaction is called immediate hypersensitivity, because it begins rapidly, within 
minutes of antigen challenge and because it has major pathologic consequences 
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 (hypersensitivity).  In the most extreme systemic form of this reaction, called anaphylaxis, 
mast cell-derived or basophil-derived mediators can cause bronchial constriction to the 
point of asphyxiation, massive tissue edema and cardiovascular collapse leading to death 
(62). 
As with the mechanisms of autoimmune diseases discussed above, the genetic 
analysis of atopic diseases also indicates that the susceptibility to atopy also arises from 
multi-genenic interactions and effects of environmental factors (63-65). Epidemiologic 
evidence from first-degree family members of individuals with atopic diseases and 
disease predisposition studies of large numbers of twins clearly indicate a strong genetic 
component to atopic disease (63, 64, 66, 67). The prevalence of allergic diseases 
including asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis in first-
degree relatives of diseased individuals is significantly higher than in relatives of non-
diseased individuals. Also, in these studies, the genetic impact can be viewed as 
independent from geographical components, since these studies were performed on 
different continents (66-68). The analysis of monozygotic and dizygotic twins 
demonstrates that the quantifiable traits of allergic diseases, such as serum IgE levels and 
skin test reactivity, show much stronger association with allergic disease in monozygotic 
twins than those in dizygotic twins (69). Similar to autoimmune genetic studies, whole 
genome screens and linkage analyses have revealed several susceptible loci, and related 
candidate genes have been identified in both human and murine models (63). Besides 
genetic effects, multiple environmental factors, such as temperature, molds, air pollutants, 
and smoke, also contribute to susceptibility to allergic diseases (65, 70-72).  
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 The allergen specific immunotherapy (SIT) is a common and effective treatment 
for atopic diseases. However, its specific mechanism of action is not well understood. 
Generally, the SIT is thought to modulate the immune response and decrease the 
sensitivity to environmentally innocuous antigens (73). The operation of SIT is that small 
but increasing quantities of antigen are administered subcutaneously over a period of 
hours or more gradually over weeks or months. As a result of this treatment, specific IgE 
levels decrease and IgG titers often rise, perhaps further inhibiting IgE production by 
neutralizing the antigen and by antibody feedback (74).  It is also possible that 
immunotherapy may work by inducing specific T cell tolerance or by changing the 
predominant phenotype of T helper cells from Th2 to Th1 (62, 75, 76).  Recently, IL-10-
secreting T regulatory cells have been proposed to modulate allergic responses and the 
SIT may, at least, in part restore the normal function of regulatory T cells to control the 
allergic responses (77, 78).   
 
Gene expression profiling by microarray 
As discussed above, because of the multigenic features of autoimmune diseases 
and atopic diseases, the microarray technology opened new avenues with great 
advantages to studying multigenic diseases. Instead of studying expression levels of a 
single gene or a handful of genes, the microarray can screen the expression pattern of tens 
of thousands genes simultaneously and provide an expression signature of a specific state 
in certain types of cells, the microarray data has been used to provide valuable 
information about disease phenotype, progression, prognosis, and responses to certain 
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 therapies (79-86). Thus, the understanding of the molecular signatures of immune-
mediated diseases may open a variety of potential diagnostic and therapeutic avenues. 
Autoimmune and atopic diseases arise from complex interactions between multi-
genetic products and environmental factors. Microarray technology has the advantage of 
screening levels of tens of thousands gene transcripts in a given experiment 
simultaneously. Therefore, this high throughput technology provides a powerful platform 
to study the complex network of gene expression in these immune-mediated diseases. It 
is thought that changes in gene expression profiles may reflect disease classification or 
identity, disease progression, disease activity, other disease manifestations, and may 
predict the direction of future developments. Therefore, gene expression profiling may 
provide valuable information about underlying mechanisms or pathways of diseases, 
diseases subtypes or classification, responses to treatment or environmental factors and 
information about future diseases activity. Thus, the gene expression profiling technology 
may shed light on discovering new biomarkers for diseases typing, new diagnostic or 
prognostic methods, and may help identify underlying causes that could lead to design of 
improved therapies or drugs to treat these diseases. 
 
Application to autoimmune diseases 
Gene expression profiling identified a common profile in the peripheral blood 
mononuclear cells (PBMC) among four different autoimmune diseases-IDDM, SLE, MS 
and RA (79), and the genes most differentially expressed are those that encode proteins 
involved in apoptosis, cell cycle progression, cell differentiation and cell migration. Four 
groups have independently discovered a specific “IFN signature” gene expression profile 
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 in PBMC and whole blood in individuals with SLE (83, 87-90). Microarray analysis of 
RA has suggested that there are specific molecular signatures of gene expression that are 
present in the PBMC of individuals with RA (91) and a specific gene expression 
signature exists in recent onset RA (early RA, ERA), which shows overlap with a subset 
of patients with systemic lupus erythematosus (80).  The specific signature for ERA has 
potential clinical application since it may permit early identification of patients that will 
develop RA and provide for earlier treatments that may prevent or delay morbidity and 
mortality.  In addition to PBMC, synovial tissue samples have also been examined to 
identify unique gene expression profiles associated with RA (92, 93). Autopsy samples 
were also used to perform gene expression profiling in MS (81, 94). The comparison of 
gene expression in PBMC between SLE and MS showed a common pattern (95).  
Therefore, all the results of gene expression profiling of autoimmune diseases indicates 
that gene expression signatures are both common to several autoimmune diseases and 
unique to a given property of an individual autoimmune disease. Theses results are 
consistent with genetic linkage studies that demonstrate the existence of shared 
susceptibility loci among several different autoimmune diseases and loci that are unique 
for a given autoimmune disease.  
 
Application to atopic diseases 
There are a few gene expression profiling studies in atopic disease. The gene 
expression profiling of nasal mucosal biopsy samples from patients with allergic rhinitis 
demonstrates that this expression profile is dominated by immunoglobulin, especially 
IgA, that may play a role in eosinophil degranulation (96). Another study comparing gene 
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 expression profiles in PBMC between atopic individuals and unaffected individuals 
suggests up-regulation of pro-survival signals in atopic individuals compared to healthy 
controls, which may be the underlying mechanism of long-lasting hypersensitivity 
responses in atopic individuals (97). Microarray based on the genes that are reported to 
be relevant in pathogenesis of atopic diseases were designed and were successfully used 
to diagnose atopy and asthma and assess disease activity (98). A differential gene 
expression profile has also been identified in bronchial tissues of asthmatic individuals, 
and strikingly, one third of the differential genes expression profile is corrected by 
inhaled corticosteroid treatment (99). This result suggested that the therapy did change 
the specific gene expression profile, but only partial of them, and the expression changes 
of these genes may be used to monitor the responses to this therapy. 
Since the first application of microarray technology more ten years ago (100), the 
approach has rapidly become a standard technology used in almost every area of 
biomedical research. Most applications have been performed in cancer research. The 
gene expression profiling in cancer has been successfully used to diagnoses and classify 
the types/subtypes of cancers (85, 86, 101-103), evaluate prognosis of cancers (104-109) , 
predict the responses to certain treatments (110-113). Under controlled conditions, such 
as the same type tissue used for the microarray, the same hybridization protocols and the 
same microarray platforms-DNA array or oligo arrays, the results of gene expression 
profiling from different groups are fairly consistent regardless of the iteration of 
microarray experiments between or within the laboratories (114). Although clinical uses 
of microarrays are still experimental and complicated, they are beginning to show 
promise in clinical application. The first microarray-based tool for cancer diagnosis 
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 (Oncotype DX, made by Genomic Health Inc.) has entered the market and used for 
clinical diagnosis of breast cancer. It is for helping to predict the likelihood of breast 
cancer recurrence in women with newly diagnosed, early-stage invasive breast cancer. 
In contrast, only a few studies of gene expression profiling have been performed 
in autoimmune and atopic disease research. As describe above, its high throughput 
feature makes it an ideal tool to study these multifactoral diseases. With the development 
of bioinformatics tools and easy handling protocols, the microarray technology should 
gain more and more attention to investigators pursuing research into autoimmune 
diseases and atopic diseases. It cannot only help to make scientific discoveries but will 
also improve clinical interventions to these diseases. 
 
Gene expression levels as quantitative genetic traits 
Gene expression profiling methods have been widely used in a variety of areas of 
biomedical science. Recently, several groups have combined gene expression profiling 
with genetic linkage analysis (115-119). In these studies, they treated the gene expression 
level as a quantitative trait and identified the genetic loci that control this trait by linkage 
analysis. These studies clearly demonstrate in several model systems that the transcript 
level of a given gene in a given tissue can be an inherited trait (115-119).  In our study to 
examine origins of gene expression signatures in autoimmune disease, we found that 
unaffected first-degree relatives of individuals with autoimmune disease share a portion 
of the gene expression profile observed in individuals with autoimmune disease (120).  
The genes that make up this overlapping profile are among the same genes that are 
differentially expressed in a number of different autoimmune diseases (79).  This argues 
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 that a portion of the gene expression profile observed in autoimmune disease is a familial 
or genetic trait rather than a product of the disease process. The evaluation of the 
correlation of parent-offspring pairs by levels of gene expression also confirms that 
expression levels of previously identified autoimmune signature genes correlate between 
parent and offspring indicating that they are governed by heredity. 
 
Specific Aims 
Autoimmune diseases and atopic diseases are immune-mediated diseases which 
exhibit the clinical manifestations of uncontrolled excessive immunological response to 
self-antigens or innocuous environmental allergens. The underlying molecular and 
cellular mechanisms of diseases pathogenesis have been pursued for decades, a large 
body of evidence has supported the idea that multigenetic interaction, environmental 
factors and stochastic events all contributed to disease susceptibility (1, 2, 18, 32, 121). 
Genetic linkages studies have been performed in humans and rodent models, the results 
indicated that multiple disease susceptibility genes exist, and some autoimmune disease 
susceptible loci are even co localized between human and rodent models. 
 In order to take the challenge of understanding this multigenetic regulation 
network in these immune-mediated diseases, the gene expression profiling method has 
been introduced into the autoimmune diseases and atopic diseases research. The gene 
expression profiling can determine the transcript level of thousands of genes 
simultaneously, thus providing the systemic image of these multigenetic interaction 
networks that may involve in diseases pathogenesis. 
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 With application of microarray technology, we compared the gene expression 
profiles of four different autoimmune diseases-RA, MS, IDDM, and SLE. Strikingly, all 
these four different autoimmune diseases shared a common gene expression profile, and 
interestingly, the unaffected family members of autoimmune diseases individuals also 
shared this profile (79).  
Since the gene expression signature has also been shared with unaffected family 
members of individuals with autoimmune diseases and further report indicates that a 
portion of these genes expression levels exhibit significant correlation between family 
pairs than non-family pairs (120). Therefore, the influence of familial resemblance may 
mask the specific expression pattern only due to autoimmune diseases phenotype. Thus, 
in chapter III of this thesis, we identified the gene expression signature of PBMC 
exclusively associated with the autoimmune disease phenotype and without the influence 
of familial resemblance.  
Atopic diseases are also a group of immune-mediated diseases, and multigenetic 
interaction also contributes to susceptibility of the atopic diseases. We already identified 
a unique gene expression signature of PBMC existing in autoimmune diseases, in specific 
aim 2 of this thesis, we tried to determine if a unique gene expression signature of PBMC 
also exists in individuals with atopic diseases, and if this expression signature is similar 
as the signature of autoimmune diseases.  
Gene expression profiling has been used not only to determine the specific disease 
phenotype, but also been used to monitor the responses to certain therapies and to 
evaluate the prognosis of patients. All these applications have been actively performed in 
cancer research, but not in autoimmune diseases or atopic diseases study. Therefore, in 
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 chapter IV and V, we tried to advance our gene expression profiling method to the 
application of monitoring the transcripts level changes upon immunotherapy in 
individuals with allergic rhinitis, and we also tried to identify the predictor genes that can 
be used to evaluate the disease course of early RA patients. 
The murine models of autoimmune disease have been greatly used in studying the 
pathogenesis of autoimmune disease and several susceptible loci overlap between human 
and mouse. Therefore, in chapter VI of this thesis, first, we tried to determine if there is a 
unique gene expression profile in T cells of autoimmune diseases murine models-NOD 
mice and NZM mice, and second, we compared them with each other and with their 
human counterpart-human type I diabetes and systemic lupus erythematosus to examine 
if there is any overlap of differentially expressed genes or pathways between human 
autoimmune diseases and murine models, which may be the important contributor to 
disease pathogenesis.  
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 CHAPTER II 
 
METHODS OF GENE EXPRESSION PROFILING 
 
 Microarrays can be grouped into two categories according to the probes on the 
solid support media- cDNA arrays and oligonucleotide arrays. As for cDNA microarray: 
the target mRNA is reverse-transcribed to cDNA, and during the reverse transcription 
process, the cDNA is labeled with a fluorescent dye (Cy3 or Cy5)-two channel 
microarray, or radioactive nucleotide (33P)-single channel microarray. Then the labeled 
cDNA is hybridized to the probes (cDNA clones) on the microarray slides or membranes. 
After washing away the unbound cDNAs, the array is scanned and an image of the array 
is generated. In the image, the fluorescent intensity or the radioactive intensity of every 
spot on the array directly correlates the expression level of this cDNA clone in the sample 
(122). As for oligonucleotide microarray, there are two types of microarrays, two-channel 
microarray which is similar as the two-channel cDNA microarray described above, and 
single channel microarray such as commercial microarrays from Affymetrix Inc. As for 
the Affymetrix single channel microarray, the target RNA is reversely transcribed into 
cDNA and further was synthesized as biotin-labeled cRNA and hybridized onto this 
microarray, after staining with antibody conjugated phycoerythrin, intensity of each 
probe spot is identified (Expression analysis technical manual, Affymetrix, Inc). Also on 
this microarray, each probe-oligonucleotide is designed to be perfectly complementary to 
a target sequence and a partner probe is generated that is identical except for a single base 
mismatch in its center. These probe pairs, called the Perfect Match probe (PM) and the 
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 Mismatch probe (MM), allows the quantization and subtraction of signals caused by non-
specific cross-hybridization. The difference in hybridization signals between the partners, 
as well as their intensity ratios, serves as indicators of specific target gene transcript level 
(Data analysis fundamentals manual, Affymetrix Inc).  
In this study, we used two types of cDNA microarray : fluorescent labeled cDNA 
microarrays (cDNA clone set printed on the glass) in murine model study, and 
radioactive labeled cDNA microarrays (cDNA clone set printed on the nylon membrane) 
in human diseases study. To generate data from the fluorescent-labeled cDNA microarray, 
two dye tags (Cy5, Cy3) are used to label the experimental sample (Cy5) and the 
reference sample (Cy3).  After the image is generated, the ratio of intensities of Cy5 and 
Cy3 is calculated and this represents the relative expression level of a cDNA clone or 
gene in the test sample compared to the reference control. A schematic of this process is 
shown as in Figure 2-1: 
 
 
Figure 2-1. Flow chart of process of fluorescent microarray. 
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 We also used radioactive labeled cDNA microarray membranes. As above, total 
RNA is reverse-transcribed and simultaneously radioactively labeled by incorporation of 
33P dCTP in the reverse transcription reactions. These labeled cDNAs are purified and 
hybridized to cDNA probes on nylon membranes.  A phosphorimaging system detects the 
intensity of the each spot on the array, and the image is created and loaded into software 
(PathwaysTM) for basic preprocessing according to the software manual, such as 
importing image, aligning the image, identifying intensity of the spots on the filer and 
normalization. After processed by Pathways software, the expression value of each 
cDNA clone on the array is divided by the average intensity of the whole dataset 
(normalization); therefore, the average intensity of all the cDNA clones for each 
experiment is 1.0. The flow chart of this process is shown as Figure 2-2.  
 
 
Figure 2-2. Flow chart of microarray with radioactive labeled probe. 
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 Microarray data analysis- preprocessing 
 The raw data obtained from Pathways software needs further processing before 
performing data analysis. In this study, we used Cluster 3.0 software (123) to perform 
preprocessing because of the ease of data manipulation. 
Data filtering: the first step is data filtering which removes certain genes that do 
not have the desired properties.  In our case, genes with constant levels of expression 
across all samples are removed to decrease the dataset to a smaller size. In general, 
filtering strategies utilize the threshold of variance of gene expression across all the 
samples or the threshold of a statistic (124). The filtering conditions are arbitrary and 
there is a general danger of “losing data”.  We used the first strategy, filtered the data by 
selecting those genes whose standard deviation of expression levels across all samples 
exceeded 1.0.  These genes were used for further processing. 
Log-transformation: The filtered data next undergoes log2 transformation. Log-
transformation is the general step to preprocess normalized data (125, 126) because log-
transformation makes the quantitative distribution of over- and under-expressed genes 
symmetrical (126). Log-transformation also provides a good approximation of the normal 
distribution (127) and can be applied to original intensity values or ratio values. Different 
log bases can be used and will generate identical results. In our studies, we used log2 
transformation of the normalized data. 
Centralization: centralization is sometimes categorized into the normalization step. 
It is used to correct the systemic bias arising from differences in mRNA concentration or 
quality and for differences in labeling efficiency. These biases have the effect of 
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 multiplying values for all genes by a fixed scalar. Mean or median centering of the data 
in log-space has the effect of correcting this bias (122, 128). 
 Normalization: All the raw microarray data are normalized to permit comparison 
among the different groups of microarray experiments, such as a treated group and a 
control group. There are several normalization methods for microarray data analysis, 
such as intensity averaging, ratio averaging, Lowess normalization, exogenous control 
genes, and house keeping genes (128). In this study, we used the built-in normalization 
method in Cluster 3 software.  This method multiplies all values in each row of data by a 
scale factor S to normalize the log transformed mean centralized data so that the sum of 
the squares of the values in each row is 1.0 (a separate S is computed for each row) (129).  
After all these preprocessing steps, we obtain a log-transformed, mean polished, 
and normalized dataset. It is suitable for further advanced microarray analysis. 
 
Microarray data analysis-advanced microarray analysis 
Useful terms: gene expression matrix and expression vectors. Gene expression 
matrix refers to a dataset of a combination of a number of microarray experiments, as 
shown in Figure 2-3. Rows represent hybridization intensities to different cDNA clones 
across all the experiments and columns represent several microarray experiments. The 
color of each cell of the matrix represents the relative expression of a gene in an 
experiment. 
 
 
 24
  
Figure 2-3. Gene expression matrix.  The color codes denote the relative expression level of a 
gene in a microarray experiment. The red color represents the relative expression level is greater 
than 1, and green color represents the expression level is less than 1. The black color represents 
the relative expression level is 1 (log21=0). 
 
 
Gene expression vectors are represented by the values of expression of an individual gene 
over the range of experiments. Similarly, experiment vectors are represented by the 
values of all the genes in this experiment (Figure 2-4). 
 
 
Figure 2-4. Gene Expression Vectors encapsulate the expression of a gene over a number of 
microarray experiments. 
 
As for advanced analysis of microarray data, we generally have three types of 
tools. First, supervised or unsupervised methods are used to categorize the data into 
different groups that may correspond to certain biological classifications. In this study, 
we used unsupervised methods: hierarchical clustering, principal component analysis, 
and gene distance matrix demonstration; supervised methods: significance analysis of 
microarray, support vector machine. Support tress analysis was also used to evaluate the 
reliability of the clustering results (130).  Based upon the information we developed, we 
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 also identified the genes whose expression profile can be used to predict phenotypes of 
other samples.  This mission is carried out by support vector machine analysis.  The 
leave-one-out cross-validation (LOOCV) by support vector machine analysis can be used 
to internally validate original data and evaluate predictability.  Third, for certain sets of 
gene signatures obtained by microarray, we used EASE analysis to reveal the intrinsic 
biological themes, which may lead to further functional assays to identify the potential 
biologically relevant pathways. Basic mechanisms about these methods are as below: 
HCL (Hierarchical clustering): The algorithm of HCL begins with each data point 
as a separate cluster, and during the clustering process of HCL, similar genes are joined 
into the same groups based upon differences or similarities in expression levels. The 
iterative process continues with the joining of resulting groups based upon their similarity 
until all groups are connected in a hierarchical tree.  The similarity of expression of genes 
or clusters during HCL process is determined by the program setting of distance metrics 
to measure the distance of two gene vectors and linkage methods to determine the 
distance between two clusters (128).  In this study, euclidean distance is calculated to 
measure the distance metric and average linkage is used as the linkage method to 
determine the distance between two clusters. There are three linkage methods in the 
software: single linkage, complete average, and average linkage that can be viewed as the 
comprised method of the former two linkage methods. The average linkage uses the 
average of all pair-wise distances between gene vectors in one cluster and vectors in the 
other cluster (131). 
ST (support tree clustering): ST is used to identify hierarchical trees and to show 
the statistical support for the cluster of the trees, based upon Jackknife re-sampling of the 
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 data (130). Jackknife re-sampling takes each expression vector and randomly omits a 
sample. This method produces expression vectors that have one fewer sample and this is 
often done to minimize the effect of single outlier values (130, 132). For each re-
sampling process, a HCL is performed and the result is compared to the original 
clustering result.  The percentage of the original clustering results that occur during the 
number of re-samplings indicates the level of reliability or support for the clustering 
result. 
GDM (gene distance matrix): GDM is used to generate a distance metric matrix to 
demonstrate the similarity between samples (gene vectors or experimental vectors) and 
thus the groups that contain the samples (gene group or experiment group).  The distance 
metric (Euclidean Distance) is calculated between two samples (vectors) to provide an 
intuitive and comprehensive view of the distance (or similarity) between any two samples.  
These distances are depicted as a colored matrix representing all sample-to-sample 
distances. The intensity of the color represents the distance or similarity between the two 
samples. 
PCA (Principal Component Analysis): PCA is an exploratory multivariate 
statistical technique that allows the identification of key variables (or combinations of 
variables), principal components, which represent a multi-dimensional data set (for 
example, a number of gene expression variables in a number of samples). Therefore, the 
PCA reduces the dimensions of the original dataset and magnifies the tendency of the 
data.  In this way, the underlying overall relationships of the data can be uncovered. 
Generally, the two or three most representative principal components are used to project 
all the data points to a two- or three- dimensional space (133, 134). 
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 SAM (Significant Analysis of Microarray): SAM analysis is used to identify the 
significant genes based on differential expression between different groups according to 
initial classification. SAM was specifically developed for analysis of genome-wide 
expression data (135). Briefly, SAM uses the standard deviation of repeated gene 
expression measurements to assign a score to each gene.  It estimates a false discovery 
rate (FDR, the proportion of genes likely to be identified as significant genes by chance) 
by permutation of the data for a particular score.  SAM analysis ascertains that genes 
identified as differentially expressed do not arise from a random fluctuation of the large 
quantity of data generated (135). FDR is used to evaluate the statistical significance of 
the gene set identified by SAM.  It is defined as the expected proportion of falsely 
identified genes (V) among the total number of identified significant genes (R) 
(FDR=V/R, V and R are calculated by the program).  In this study, the FDR=0.00000, 
which means FDR< 10-5.  
SVM (Support Vectors Machine): SVM is a supervised learning method. The first 
step for SVM is to establish the training set. For example, samples can be divided into 
two separate classes, such as under two different treatment methods, two different 
prognosis statuses, these samples are used to form a training set in which any sample can 
be labeled positively if it’s a member of a certain class or negatively if it’s a non-member 
of that class but a member of the other class. Using the training set, the SVM is capable 
of learning to determine if a sample is a member or non-member of a given class. By 
complicated mathematic computations, SVM records the expression features of the class, 
which it learned from training set. These features can be used to determine if new 
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 samples (test sets) are members or non-members of a given class according to the 
expression pattern of the samples in test set (136, 137). 
LOOCV (leave one out cross validation): in this study, we used the LOOCV 
feature of SVM to validate our results (128, 130). LOOCV analysis employs SVM to 
perform multiple permutations. At every permutation, one of the samples is removed and 
the remaining samples are used as the training set to determine the classification of the 
removed sample. After the LOOCV process, the final classification of each sample is 
determined by the rest of the samples. LOOCV is a very useful statistial tool for 
validating the classification results when there is no independent test set available for 
validation (102, 109, 138). 
 EASE (Expression Analysis Systemic Explorer): The Expression Analysis 
Systemic Explorer (EASE version 2.0) is used to search for significant biological 
categories within specified gene lists. EASE analysis will report a group of over-
represented biological categories that are represented in the gene list (test list, such as 
differentially expressed genes). A statistic reports the probability that the prevalence of 
the particular biological categories within the test gene list is due to chance alone given 
the prevalence of the biological categories in the population of genes under study (all 
“genes” loaded into software for analysis) (139-141). For detailed description, please 
refer to the following chapters. EASE analysis provides a powerful tool to identify the 
over-represented biological categories in a given gene list, with the information of 
significant biological categories within the genes, we can advance our investigation from 
transcripts level measurement to biological functional studies. This may shed light on 
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 identifying new biological pathways or genes that may be important for pathogenesis or 
status of a given disease. 
 30
 CHAPTER III 
 
IDENTIFICATION OF GENE EXPRESSION SIGNATURES IN AUTOIMMUNE  
DISEASE WITHOUT THE INFLUENCE OF FAMILIAL RESEMBLANCE 
 
 
Abstract 
Even though autoimmune diseases are heterogeneous, believed to result from the 
interaction between genetic and environmental components, patients with these disorders 
exhibit reproducible patterns of gene expression in their peripheral blood mononuclear 
cells.  A portion of this gene expression profile is a property of familial resemblance 
rather than autoimmune disease.  Here we wanted to identify the portion of this gene 
expression profile that is independent of familial resemblance and determine if it is a 
product of disease duration, disease onset, or other factors.  By employing supervised 
clustering algorithms, we identified 100 genes whose expression profiles are shared in 
individuals with various autoimmune diseases but are not shared by unaffected family 
members of individuals with autoimmune disease or by controls.  Individuals with early 
disease (1 yr after onset) and established disease (10 yr after onset) exhibit a near 
identical expression pattern suggesting that this unique profile is a product of disease 
onset rather than disease duration. 
 
Introduction 
Autoimmune diseases are heterogeneous diseases believed to arise from immune-
mediated attack against self-antigens.  Both genetic and environmental factors play 
important roles in their onset and pathogenesis (1, 142, 143). Epidemiologic data along 
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 with genetic linkage studies clearly support the presence of a genetic contribution to 
susceptibility to autoimmune disease (2, 37, 40, 41, 144-148).   Linkage studies have 
demonstrated the presence of susceptibility loci that are shared among multiple 
autoimmune diseases (2, 41, 144) and those that are unique for a given autoimmune 
disease (40, 145, 146). 
Specific gene expression profiles have also been found in the peripheral blood 
mononuclear cells (PBMC) of individuals with autoimmune diseases (79-81, 83, 87-91, 
149, 150).  Some of these, for example, an “IFN-signature” has been found in systemic 
lupus erythematosus (SLE) that is a function of disease severity (87) and an early disease 
signature has been found in rheumatoid arthritis (RA) (80), seem to be unique to a given 
type of autoimmune disease.  In addition, we have described a gene expression signature 
that is shared among several autoimmune diseases, including RA, SLE, type 1 diabetes 
(IDDM), and multiple sclerosis (MS) (79).  Thus, gene expression signatures that are 
both common to several autoimmune diseases and unique to a given property of an 
individual autoimmune disease exist.   
Studies on the genetics of gene expression have been performed in model systems 
and demonstrate that a portion of the gene expression profile or transcript level in a given 
tissue is an inherited trait (115-117).   Thus, transcript levels are heritable phenotypes and 
this has been demonstrated under a variety of conditions across a range of species (118).  
A power of this approach is that linkage analysis can identify loci that control variation in 
transcript levels.  Knowledge of the genes that encode these transcripts will undoubtedly 
stimulate identification of “candidate genes” that reside in loci identified by linkage 
analysis.  Along these lines, we have asked if unaffected first-degree relatives of 
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 individuals with autoimmune disease share gene expression profiles observed in 
individuals with autoimmune disease.  We find that these two groups share an 
overlapping gene expression profile (120).  The genes that make up this overlapping 
profile are among the same genes that are differentially expressed in a number of 
different autoimmune diseases.  This argues that a portion of the gene expression profile 
observed in autoimmune disease is a family trait that may arise through genetic 
mechanisms.    
Therefore, we wanted to determine if we could identify exclusive gene expression 
signatures shared by individuals with autoimmune disease but not by unaffected family 
members (refer to unaffected family members of individuals with autoimmune diseases, 
hereafter) or by control individuals.  We also wanted to determine if this gene expression 
signature was a function of onset of autoimmune disease or duration of autoimmune 
disease. 
 
Materials and methods 
 
Patient populations 
 This study consists of the following groups as described in the text: 
(1) Eight healthy control individuals without active infection or family history of 
autoimmunity. 
(2) Fifty-four individuals with autoimmune diseases: SLE (systemic lupus 
erythematosus, n=19), RA (established rheumatoid arthritis, average disease 
duration of 10.5 ± 2.6 yr, n=9), ERA (early rheumatoid arthritis, average disease 
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 duration of 1.1± 0.3 yr, n=17), IDDM (insulin dependent diabetes mellitus, n=5), 
and MS (multiple sclerosis, n=4). 
(3) Eight unaffected family members of individuals with autoimmune diseases (SLE 
and RA). 
All autoimmune patients satisfied established criteria for diagnosis of their respective 
diseases. Human subject studies were approved by the committee for the protection of 
human subjects of the Vanderbilt University Institutional Review Board. 
 
Sample preparation and microarray procedures 
Analysis procedures presented here comply with MIAME (minimal information 
about a microarray experiment) guidelines established by the Microarray Gene 
Expression Data Society (www.mged.org).  PBMC were isolated from 20 ml heparinized 
blood on a Ficoll-Hypaque gradient.  All samples were processed within one hour of 
blood collection. Total RNA was isolated with Tri-Reagent (Molecular Research Center. 
Inc., Cincinnati OH), 5 µg RNA was reverse-transcribed by reverse transcriptase 
(Superscript II, Invitrogen Corporation, Carlsbad, CA) in the presence of 33P-dCTP.  
Labeled probes were purified using a Bio-Spin 6 Chromatography Column (Bio-Rad 
Laboratories, Inc., Hercules, CA).  Before hybridization, GeneFilters membranes (GF-
211,4133 human cDNA clones were printed on this membrane, Research 
Genetics/Invitrogen Corporation, Carlsbad, CA) were washed in boiled 0.5% SDS, 
saturated with 5.0 ml Microhyb solution (HYB125.GF, Research Genetics/Invitrogen 
Corporation, Carlsbad, CA).  Filters were treated with pre-hybridization reagents (5.0 µg 
Human Cot-1 DNA and 5.0 µg Poly dA, Invitrogen Corporation, Carlsbad, CA) in a 
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 hybridization roller tube (Midwest Scientific, St. Louis MO) for 2 hours at 42 ºC.  
Purified, labeled probes were denatured and added to roller bottles containing filters and 
pre-hybridization solution.  GeneFilters membranes were hybridized overnight at 42 ºC. 
After hybridization, membranes were washed (1st and 2nd wash: 2X SSC, 1% SDS at 50 
ºC for 20 minutes; 3rd wash: 0.5X SSC, 1% SDS at 55 ºC for 15 minutes).  After washing, 
membranes were exposed to imaging screens for 24 hr and the screens were scanned by a 
phosphorimager (Molecular Dynamics/Amersham Biosciences, Piscataway NJ).  
Acquired images by the phosphorimager were loaded into Pathways 4.0 software 
(Research Genetics/Invitrogen Corporation, Carlsbad, CA).  The relative intensity of each 
spot on the membrane was determined and the microarray dataset was subjected to 
further analysis using the different analytical platforms. Microarray data have been 
deposited into GEO database, accession number: GSE3447. 
 
Data Analysis 
Raw microarray data were imported into Cluster (version 3.0) (123) for pre-
processing. For the analysis, we filtered the data by selecting those genes whose standard 
deviation of expression levels across all samples exceeded 1.0.  These genes were used 
for normalization and analysis.  Filtered data were normalized and loaded into the TIGR 
MultiExperiment Viewer (MEV version 3.1) (130) from the Institute of Genomic 
Research (Rockville, MD, USA).  The following data analysis modules of MEV were 
used for the analysis: HCL (hierarchical clustering), SAM (significant analysis of 
microarray), ST (support tree clustering), PCA (principal components analysis) and GDM 
(gene distance matrix).  
 35
  SAM (significant analysis of microarray): Microarray data were statistically 
analyzed using the SAM algorithm, which was specifically developed for analysis of 
genome-wide expression data (135). Briefly, SAM uses the standard deviation of repeated 
gene expression measurements to assign a score to each gene.  It estimates a FDR by 
permutation of the data for a particular score.  SAM analysis ascertains that genes 
identified as differentially expressed do not arise from a random fluctuation of the large 
quantity of data generated (135).  
 FDR was used to evaluate the statistical significance of the gene set identified by 
SAM.  It is defined as the expected proportion of falsely identified genes (V) among the 
total number of identified significant genes (R) (FDR=V/R, V and R are calculated by the 
program).  In this study, the FDR=0.00000. 
 ST (support tree clustering): ST was used to identify hierarchical trees and to 
show the statistical support for the nodes of the trees, based upon Jackknife re-sampling 
of the data. 
 PCA (principal components analysis): PCA is used to identify the key variables 
(or combination of variables), principal components, which represent a multi-dimensional 
data set (for example, a number of gene expression variables in a number of samples).  
The three most representative principal components are used to map each element to a 
three dimensional viewer (134).  
GDM (gene distance matrix): We used the GDM to calculate the distance metric 
(Euclidean Distance) between two samples to provide an intuitive and comprehensive 
view of the distance (or similarity) between any two samples.  These distances are 
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 depicted as a colored matrix representing all sample-to-sample distances. The intensity of 
the color represents the distance or similarity between the two samples. 
Detailed descriptions of the applications of these modules are provided in the 
results section and are also available in the TIGR MEV manual (130). 
 
Biological process categorization by gene ontology 
EASE: the Expression Analysis Systemic Explorer (EASE version 2.0) was used 
to search for common biological themes within gene lists generated by our microarray 
analysis.  EASE assigns identified genes to “GO: Biological Process” categories of the 
Gene Ontology Consortium (www.geneontology.org) (139-141) and categories are tested 
statistically (EASE: Fisher’s Exact Test) to identify over-represented categories of 
identified genes within the biological process system.  Significant functional categories 
are those with the number of list hits (LH) of at least 2 with a P value < 0.05 (EASE, 
Fisher’s Exact Test with Bonferroni correction). 
 
Statistical analysis 
Euclidean Distance:  In our study, Euclidean distance was used to build the 
hierarchical clustering (unsupervised, SAM supervised, and support tree).  It was also 
used to calculate the distance of groups in the gene distance matrix (GDM) (130).  
Euclidean distance was used to calculate the distance metric that reflects the distance 
between two objects in space. Euclidean distance extends to as many dimensions as 
present in the expression vectors to be compared.  In our case, the expression vectors are 
represented by the values of expression of an individual gene over the range of samples 
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 (or in GDM analysis of this study, the expression vectors are represented by the values of 
expression over the range of identified genes for an individual sample).  The calculation 
of Euclidean distance is:  
 
Where distance, d (u, v) can range from 0 to positive infinity and ui and vi represent the 
two vector values, m represents the number of samples (or in GDM analysis of this study, 
m represents the number of identified genes) used in this calculation. 
Jackknife re-sampling: Jackknifing takes each expression vector and randomly omits a 
sample. This method produces expression vectors that have one fewer sample and this is 
often done to minimize the effect of single outlier values (130, 132). 
 
Results 
 
Supervised gene expression profiling permits separation of unaffected family members 
from individuals with autoimmune diseases 
 
Previously we reported that individuals with different autoimmune diseases share a 
common gene expression profile and that unaffected first-degree relatives of individuals 
with autoimmune disease share a portion of this profile (79, 120).  Here, we wanted to 
determine if we could identify a second set of genes whose expression profiles permit 
separation of individuals with autoimmune disease from unaffected family members. To 
do so, we increased the number of autoimmune samples from 8 to 54, and used numbers 
of controls (N=8) and unaffected family members (N=8) similar to our previous analysis. 
Of the 4133 genes for which we had expression data, 752 genes passed filtering condition 
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 at a standard deviation of 1 using the Cluster software.  After filtering, expression data 
for the 752 genes were normalized and loaded into the TIGR MEV software.  We 
performed a significant analysis of microarray (SAM) study using these 752 genes. For 
the first step, we set initial classifications: control individuals group, unaffected family 
members group, and autoimmune individuals group.  Since the false discovery rate (FDR, 
the proportion of genes likely to be identified by chance) was set to 0.00000 (FDR<10-5), 
statistically, the number of genes identified by chance is less than 1. The expression 
levels of the SAM identified 100 genes separated the samples into different groups 
according to their initial classification.  We applied hierarchical clustering algorithm to 
the gene expression profile of these 100 genes (Fig. 3-1). 
 
 
1 
2 
 
Figure 3-1. Hierarchical clustering analysis of expression data using the SAM identified 100 genes 
with support tree validation. Jackknife re-sampling was used with 1000 times to establish the 
support levels for the separate nodes or branches.  Color codes correspond to a given level of 
support for a given node. 1, 2 refer to different variation patterns of genes across the samples. 
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  The unaffected family members were grouped into a separate branch from the 
individuals with autoimmune disease, but within the same branch as the controls.  The 
only exception was that control 21 clustered with two autoimmune patients (RA08 and 
SLE05), and this small cluster was grouped together with the autoimmune disease group.  
Two major patterns of gene expression were seen. One pattern contained genes that were 
highly expressed in controls and unaffected family members and weakly expressed in 
individuals with autoimmune disease (Fig. 3-1, pattern 2).  The second pattern contained 
genes that exhibited the opposite expression pattern, weak expression in controls and 
unaffected family members and high expression in individuals autoimmune disease (Fig. 
2-1, pattern 1). 
 
Support tree analysis of the reliability of hierarchical clustering 
By increasing the sample pool size and with the assistance of supervised SAM 
analysis, we successfully separated the unaffected family members from individuals with 
autoimmune disease.  In order to test the reliability of the hierarchical clustering results 
we obtained after SAM analysis, we performed Jackknife re-sampling 1000 times.  For 
each re-sampling process, a hierarchical clustering was performed and the result was 
compared to the original clustering result.  The percentage of the original clustering 
results that occurred during the 1000 re-samplings indicates the level of reliability or 
support of the clustering result (Fig. 3-1).  The color of the nodes denotes the support 
level of the clustering, i.e. the frequency this clustering node appeared among the 1000 
re-sampling processes.  By performing support tree analysis, we found that the branch 
containing the unaffected family members and control individuals was separated from the 
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 branch of individuals with autoimmune disease and achieved greater than 90% support by 
the Jackknife re-sampling test. Therefore, we concluded that the separation between 
unaffected family members, control individuals and individuals with autoimmune 
diseases was very reliable. 
 
Principal components analysis (PCA) 
From the above analysis, the 100 genes identified by SAM analysis permitted 
reliable separation among control individuals, unaffected family members, and 
individuals with autoimmune diseases.  In order to gain an intuitive overview of how 
these three groups were distributed in three-dimensional space according to expression 
profiles of these 100 genes, we performed principal components analysis (PCA).  PCA 
projected these three groups of individual samples (individuals with autoimmune diseases, 
healthy controls and unaffected family members) into a three-dimensional space and their 
positions in this space were determined by their gene expression profile.   
 
A B 
 
 
Figure 3-2. PCA analysis of distribution of samples according to expression levels of SAM 
identified 100 genes. (A) Projection of samples in three-dimensional space: yellow spheres 
represent control individuals, red spheres represent unaffected family members and other color 
spheres represent individuals with autoimmune disease. (B) Two-dimensional projection of 
samples onto an X-Y plane according to expression levels of SAM identified 100 genes. Black 
squares represent control individuals, red squares represent unaffected family members and other 
color squares represent individuals with different autoimmune diseases. 
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 PCA clearly separated the samples into three distinct groups in space: unaffected 
family members (red spheres), healthy controls (yellow spheres) and individuals with 
autoimmune disease (other color spheres) (Fig. 3-2 A, 3-D space, B, 2-D space).  This 
analysis demonstrated two points.  First, as individual samples, the control samples were 
more like other control samples than the non-control samples, the unaffected family 
member samples were more like other unaffected family samples than the other samples, 
and the autoimmune samples were more like other autoimmune samples than the non-
autoimmune samples.  Second, as a group, the unaffected family member samples were 
more like the control samples than they were like the autoimmune samples. This result 
essentially confirmed our hierarchical clustering results and demonstrated that the 
separation pattern may be determined by the similarity of the different groups. 
 
Gene Distance Matrix 
In order to further examine the similarity of these three groups-controls, 
unaffected family members and individuals with autoimmune disease, we examined the 
similarity among the three groups by calculating the distance metric (Euclidean Distance, 
see statistical analysis) between the samples from each of two different groups 
(unaffected family members versus controls, unaffected family members versus 
individuals with autoimmune diseases, and controls versus individuals with autoimmune 
diseases).  The result is shown in the Gene Distance Matrix (GDM) (Fig.3-3). Each 
square element within the matrix is rendered a color that represents the distance or 
similarity between the two samples associated with the element.  Color similarity 
indicates that two samples have a high degree of actual similarity.  Thus, samples with 
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 dark blue colors indicate that the corresponding two samples have a higher degree of 
similarity than the samples denoted by pale blue colors. These data indicate that the 
expression profiles of the 100 genes identified by SAM analysis have a higher overall 
similarity between the unaffected family members and the controls than that between the 
unaffected family members and the individuals with autoimmune diseases or the controls 
and the individuals with autoimmune diseases.  
 
 
 
Figure 3-3. Gene Distance Matrix (GDM). The similarity among the three groups was measured 
by calculating the distance metric between the samples from each of two different groups 
(unaffected family members versus controls, unaffected family members versus individuals with 
autoimmune disease, and controls versus individuals with autoimmune disease).  Each square 
element within the matrix is rendered a color that represents the distance or similarity between the 
two samples associated with the element. 
 
 
This result is consistent with the PCA analysis (Fig. 3-2) and can be considered as the 
underlying rationale for the distribution pattern of these samples in the PCA space. 
 
Composition of SAM identified 100 genes 
In our previous study, we identified a shared gene expression signature in 
individuals with different autoimmune diseases (79). We examined the 100 genes 
identified by SAM.  We found that 64% (64/100) of these genes represent previously 
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 identified autoimmune signature genes (79).  We also examined the distribution of the 
autoimmune signature genes in the total 752 genes dataset (110/752) identified by the 
initial filtering.  The chi-squared test revealed that the autoimmune signature genes were 
significantly over-represented in the set of genes identified by SAM (χ2 =132.39, P<0.001, 
Chi-Squared Test).  
In order to gain an overview of the potential biological relevance of alterations in 
expression of the 100 genes identified by SAM, we performed EASE analysis to 
categorize the 100 genes identified by SAM into their biological ontology (see methods).  
We considered categories as significant if they contained at least two genes with P < 0.05 
(Fisher’s exact test with Bonferroni correction).   
 
Table 3-1. Over-represented categories in 100 genes. Biological process 
categories significantly over-represented (P < 0.05; Fisher’s Exact Test, 
Bonferroni correction applied) in 100 genes identified by SAM.  
 
Gene category   LH  EASE  Symbols 
RNA splicing   3  0.042   SF3A3; SIP1; SNRP70 
DNA damage response 2  0.042   BRCA1; TP53 
amino acid catabolism 3  0.042   ASL; ASPA; BDH 
regulation of CDK activity 2  0.042   CDKN1B; CKS2 
response to toxin  2  0.042   BPHL; EPHX2 
LH: list hits, the number of identified genes within the specific category. EASE: 
P-value, Fisher’s Exact Test, Bonferroni correction applied.  
 
 
The over-represented categories of the 100 genes identified by SAM included “RNA 
splicing”, “DNA damage response genes”, “amino acid catabolism” “regulation of CDK 
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 activity”, and “response to toxin” (Table 3-1). These results are consistent with the idea 
that lymphocytes from individuals with autoimmune disease exhibit defects in responses 
to DNA damage and cell cycle control, as we have shown previously, as well as defects 
in other processes (79, 151) 
 
Quantitative differences in gene transcript levels among the three groups 
From the above analysis we found that the 100 genes identified by SAM were 
over-represented by autoimmune signature genes and that “DNA damage response 
genes” and “regulation of CDK activity” were over-represented biological categories. 
Next we wanted to examine the quantitative variation in expression levels of the 100 
genes identified by SAM in the different groups. We divided the 100 genes into two 
groups: “autoimmune signature” genes and non-“autoimmune signature” genes according 
to our previous studies (79).   
 
 
 
Figure 3-4. Quantitative differences in gene transcript levels among the three groups. (A) 
Average expression levels (mean and standard error) of representative “autoimmune signature” 
genes within in SAM identified 100 genes among three groups are shown. (Cont vs Auto and FA 
vs Auto: P<0.001, Student’s T test) (B) Average expression levels (mean and standard error) of 
representative “non-autoimmune signature” genes in SAM identified 100 genes among three 
groups are shown (Cont vs Auto and FA vs Auto: P<0.001, Student’s T test).  
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 Comparison of expression levels of representative “autoimmune signature” genes 
demonstrated that these genes were uniformly expressed at similar levels in controls and 
unaffected family members and were expressed at considerably lower levels in 
autoimmune individuals (Fig. 3-4 A). The non-“autoimmune signature” genes displayed a 
more heterogeneous expression pattern (Fig. 3-4 B).  However, in most cases, expression 
levels of individual genes were higher in unaffected family members than in the controls 
or the autoimmune samples.  
 
Expression levels of “autoimmune signature” genes in individuals with early RA (ERA) 
 
We have previously analyzed two populations on patients with RA, one 
population with an average disease duration of 10.5 ± 2.6 yr and a second population 
with an average disease duration of 1.1± 0.3 yr (80).  Therefore, we compared the gene 
expression profiles between early RA and established RA to determine if each group 
exhibited the same expression patterns of the 100 genes identified by SAM. We found 
that these genes were highly expressed in controls and unaffected family members but 
weakly expressed in both ERA and RA samples with similar expression patterns seen in 
the two RA groups (Fig. 3-5).   
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Figure 3-5. Comparison of gene expression profiles between early RA and established RA 
samples. Expression levels (mean and standard error) of representative SAM identified genes 
were compared in individuals with early RA, individuals with established RA, unaffected family 
members and controls. 
 
 
We conclude from this comparison that expression levels of these genes change early 
after onset of rheumatoid arthritis and remain relatively constant thereafter.  We presume 
that gene expression patterns in the other autoimmune diseases follow a similar pattern.  
 
Validation analysis 
In order to validate our results, we arbitrarily divided our samples into two sets, a 
training set and a test set; each set contained 4 controls, 4 unaffected family members and 
27 individuals with autoimmune disease.  We applied the same analysis described above 
to the training set: of the 4133 genes for which we had expression data for the training set, 
722 passed filtering conditions at a standard deviation of 1.  We performed SAM using 
these 722 genes, as FDR equals to 0.00000, SAM identified 99 genes whose expression 
data accurately separated the three groups (control, unaffected family and autoimmune 
disease) with > 90% support by support tree hierarchical clustering analysis (Fig. 3-6 A). 
Next, we determined if the gene expression profile of these 99 genes could be used to 
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 discriminate the three groups in the test set.  To do so, we applied support tree 
hierarchical clustering to the test set using the expression levels of the 99 genes identified 
by the training set analysis (Fig. 3-6 B).  The autoimmune disease group was separated 
from the control and unaffected family member groups with > 90% support, except 
control 21, which clustered with RA08 in the autoimmune groups.  Under the node 
shared by the control and unaffected family groups, the control group was clustered 
together and separated from the unaffected family member group.  Next we used the gene 
expression profile of the 99 genes to perform support tree hierarchical clustering with the 
total sample pool (training set and test set).  Under these conditions, individuals with 
autoimmune disease clustered together with more than 90% support and samples from the 
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Figure 3-6. Validation analysis. (A). Hierarchical clustering with support tree validation of SAM 
identified 99 genes from training set. (B) Hierarchical clustering with support tree validation of 
SAM identified 99 genes’ in the test set. (C). Hierarchical clustering with support tree validation 
of SAM identified 99 genes’ in both training and test sets. The green bar indicates samples from 
the training set and the blue bar indicates samples from the test set. Jackknife re-sampling (1000 
times) was used to establish support levels for the separate nodes or branches.  Color codes 
correspond to a given level of support for a given node as in Fig. 2-1. 
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 training and test sets were distributed with each other under the autoimmune disease 
group node (Fig. 3-6 C).  Similarly, the control group was clustered together and 
separated from the unaffected family member group, except for control 21, which was 
clustered with SLE05 and RA08 in the autoimmune group. Within each group, samples 
from training and test sets were intermingled with each other.  Strikingly, 80 of the 100 
genes identified by SAM using the entire dataset were also identified from the training set 
only.  EASE analysis of the 99 genes identified by SAM in the training set revealed the 
same over-represented functional categories (P<0.05, Fisher’s Exact Test, Bonferroni 
correction applied) as identified from the previous 100 genes (Table 3-1). These results 
indicate that the gene expression signature identified by these methods will discriminate 
individuals with autoimmune disease from unaffected individuals, both family members 
and non-family members of affected individuals. 
 
Discussion 
Previously, we characterized a single common gene expression profile present in 
the PBMC of individuals with four different autoimmune diseases, RA, SLE, MS and 
IDDM (79).  A portion of this gene expression profile is also present in unaffected first-
degree relatives of individuals with autoimmune disease (120). Our interpretation of these 
results is that a portion of these variations in gene transcript levels is associated with 
familial resemblance rather than clinical manifestation of autoimmune disease suggesting 
that it may be of genetic origin. In this report, we tried to identify a set of genes whose 
expression profile exclusively reflected the presence of autoimmune disease without the 
influence of familial resemblance. To do this, we pre-classified control individuals (N=8), 
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 unaffected family members (N=8) and individuals with autoimmune disease (N=54) as 
three independent groups. We reasoned that increasing the sample size of the autoimmune 
class might help discriminate between the autoimmune class and the control and 
unaffected family member classes. With the assistance of supervised SAM, we 
successfully identified 100 genes whose expression profiles can discriminate individuals 
with autoimmune disease from unaffected family members and controls using 
unsupervised hierarchical clustering algorithms. By validation analysis, we confirmed 
that the gene expression signatures identified by this method could accurately 
discriminate individuals with autoimmune disease from unaffected individuals who are 
either family members or non-family members of affected individuals. 
PCA is another measure that provides an overview of gene expression data.  PCA 
essentially confirms the hierarchical clustering results.   This analysis segregates samples 
into three groups: control individuals, unaffected family members and individuals with 
autoimmune disease, based upon their distribution in three- or two-dimensional space. 
Samples from control individuals and unaffected family members are also grouped in 
closer proximity to one another than are individuals with autoimmune disease and 
unaffected family members or controls. The similarity among different groups measured 
in GDM also demonstrates the similarity of gene expression profiles among different 
groups determined their distribution in the PCA three-dimensional space. 
The 100 genes identified by SAM consist largely of previously identified 
autoimmune signature genes (79) and their expression levels are much lower in 
individuals with autoimmune disease than in control individuals or unaffected family 
members.  EASE analysis reveals that one of the most over-represented biological 
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 process categories in the 100 genes identified by SAM is the “DNA damage response” 
category that includes both TP53 and BRCA1 genes (TP53 is the gene name of p53). The 
p53 protein, which is also under-expressed in RA lymphocytes, is a central mediator of 
cellular responses to stress able to induce either cell cycle arrest or apoptosis depending 
upon the degree of stress or damage (152, 153).  Defects in lymphocyte apoptosis may 
contribute to development of autoimmunity.  For example, the MRL murine strain has a 
mutation in Fas and exhibits defects in apoptosis and develops an autoimmune-like 
syndrome (34).  Studies in murine models of collagen-induced arthritis demonstrate that 
loss of p53 function contributes to more severe lymphocytic infiltration into tissues and 
more severe joints destruction (154).  In addition, both viral and cellular factors can 
interfere with p53 expression and function (155), and the consequences may affect the 
normal expression of p53 as well as p53 effector genes- Gadd45a or  p21, and this may 
also contribute to the development of autoimmunity (156, 157).  
Interestingly, there was a report about T lymphocytes BRCA1 knockout mice 
(158). In this conditional BRCA1 knockout mouse, the peripheral T cell number greatly 
decreased due to T cell apoptosis, the author reasoned that Brca1 was responsible for 
maintaining the stability of genome, without Brca1, the cell is easy to lose its genome 
stability due to environmental stress and is susceptible to apoptosis. However, when this 
mouse was crossed to TP53 knockout mouse, the double knockout mouse (BRCA1 
knockout and TP53 knockout) almost fully restored its peripheral T cell number (158). 
From this results, also considering BRCA1 and TP53 are both substantially 
underexpressed in control group than that of autoimmune group (more than 15 fold), we 
have the hypothesis: T cells have increased population undergoing apoptosis in 
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 autoimmune individuals compared to those of control individuals, the increased apoptosis 
is due to substantially underexpressed Brca1 in autoimmune individuals; thus, the 
peripheral T cell number would be decreased due to increased apoptosis, however, p53 
was also substantially underexpressed, in parallel as double knockout mouse model(158), 
the peripheral T cell number could be partially restored; therefore, the autoimmune 
individual may experience chronic lymphopenia; finally the lymphopenia driven T cells 
homeostatic proliferation may finally result autoimmunity under autoimmune individual 
genetic setting or effects of other factors (17, 159, 160). This may suggest that 
lymphopenia can be relevant contributor to establish autoimmunity. It’s not uncommon 
that some autoimmune diseases accompany with lymphopenia (161), our results may give 
one possible explanation for lymphopenia existing in autoimmune individuals, however, 
it needs further investigation. 
    In this analysis, we have RA patients with early disease and established disease.  
Expression levels of the 100 genes identified by SAM are highly under-expressed in both 
groups compared to that of the control and unaffected family member groups and exhibit 
similar expression patterns in the two RA groups.  We conclude from this comparison 
that changes in gene transcript levels must occur at the time of disease onset or very 
shortly after disease onset.  Although we do not know the precise mechanism that causes 
these changes in gene expression after disease onset, it may arise from cell intrinsic or 
extrinsic mechanisms.  If one considers how this may occur in T lymphocytes, intrinsic 
changes may arise from alterations in lymphoid progenitor cells, selection processes 
during development in the thymus, or perhaps establishment of a chronic infection in 
progenitor or peripheral T cells.  Extrinsic mechanisms may result from alterations in the 
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 host environment such as changes in the cytokine or chemokine milieu that lymphocytes 
face in the periphery or changes in other cell types that interact with lymphocytes.  We 
believe that this will be a fruitful avenue of future investigation.   
Gene expression signatures in autoimmune disease have been widely described (79, 81, 
83, 87-91, 149, 150).  Differential expression of these genes has the potential to affect 
both onset and pathogenesis of autoimmune disease.  However, because of the complex 
genetic characteristics of autoimmune disease, the high variability of the genetic 
character of the human population and the contribution of genetics to gene expression 
(115-118), the differential expression pattern of these genes cannot be only attributed to 
the presence of autoimmune disease.   It may also reflect familial resemblance.  Both 
components should be considered in any study of gene expression profiling in human 
disease.  This may help us more accurately identify changes in gene expression that are 
strictly associated with disease without masking of the genetic components.  However, it 
must be considered that the gene expression pattern that is strictly associated with disease 
onset may not arise without the contribution of the gene expression pattern that is 
governed by genetics or familial resemblance. 
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 CHAPTER IV 
 
HIGHLY CONSERVED GENE EXPRESSION PROFILES IN HUMANS WITH 
ALLERGIC RHINITIS ALTERED BY IMMUNOTHERAPY 
 
 
Abstract 
Atopic diseases, resulting from hypersensitivity to a wide variety of allergens, 
affect 10-20% of the population. Immunotherapy is an effective treatment for atopic 
diseases, but its mechanisms are not fully understood. We studied gene expression 
profiles in the peripheral blood mononuclear cells and examined whether the individuals 
with allergic rhinitis have a unique gene expression profile and how the immunotherapy 
affect the gene expression profiles. A highly conserved gene expression profile exists in 
atopic subjects, which permitted their accurate segregation from control or autoimmune 
subjects.  A major feature of this profile was the under-expression of a variety of genes 
that encode proteins required for apoptosis and over-expression of genes that encode 
proteins critical for stress responses and signal transduction.  We also identified 563 
genes that can segregate individuals with allergic rhinitis based upon receipt of 
immunotherapy. This profile can be used to identify individuals with allergic rhinitis and 
to evaluate responses to immunotherapy.  Quantitative endpoints, such as gene 
expression, may assist clinicians faced with clinical decisions in the diagnosis of patients 
and the evaluation of response to therapy.  The knowledge of the possible genetic basis 
for immunotherapy efficacy may also lead to novel therapeutic approaches for atopic 
diseases. 
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 Introduction 
Atopic disease represents one of the major categories of immune-mediated 
disease in the human population (162, 163).  Both environmental and genetic factors 
contribute to disease onset and severity (164, 165).  One common type of atopic disease, 
allergic rhinitis, is a consequence of immediate hypersensitivity to common airborne 
allergens localized to the upper respiratory tract (73, 166).  De-sensitization by 
immunotherapy (“allergy shot”) is a common clinical treatment for atopic diseases(77) 
and can provide a possible permanent improvement in the clinical disease.  However, its 
precise mechanism is not fully understood. 
Gene expression profiling offers a powerful tool to classify human diseases, 
identify common features of clinically distinct diseases, and contribute to disease 
diagnoses. Alterations in gene expression profiles in a common cellular or tissue source 
may also permit more accurate monitoring of changes in disease activity after therapy, 
may predict patient responses to a given type of treatment, or may predict risks of 
unwanted side-effects in response to treatments (105, 112, 138, 167).  Identification of 
genes whose expression levels fulfill these goals could have significant impact on the 
decisions made by clinicians in patient treatment. 
Several groups including our own have recently reported initial results of these 
gene expression studies in human autoimmune diseases (79, 89, 149). These results 
clearly demonstrate that it is possible to use gene expression profiling to classify human 
diseases and to identify common features present in clinically distinct autoimmune 
diseases.  Therefore, in this study, using similar approaches, we aimed to determine if we 
also found conserved gene expression profiles in peripheral blood mononuclear cells 
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 (PBMC) in individuals with allergic rhinitis and if these profiles shared common features 
with those of human autoimmune disease.  We also wanted to determine if and how gene 
expression profiles in these individuals might change after immunotherapy.  Here, we 
demonstrate that individuals with allergic rhinitis have unique gene expression profiles in 
their PBMC compared to those who are not allergic or have autoimmune diseases without 
allergic rhinitis.  We also demonstrate that these gene expression profiles change in a 
characteristic way after immunotherapy.  Thus, we provide direct support for the concept 
that identification of “biomarkers” in human disease is possible and that they can be used 
to monitor responses to therapy. The identification of which gene expression pathway 
may underlie atopic diseases and is altered with immunotherapy, an effective clinical 
treatment, may provide insight into development of novel approaches to disease 
management. 
 
Materials and methods 
 
Patient populations 
Patients with allergic rhinitis (N=8; 22-58 yrs of age) had blood drawn at their 
first clinic visit before receiving allergy immunotherapy in spring and summer of 2003, 
none of them had received immunotherapy previously.  Four patients (female; 3 
Caucasians 1 African American; mean age 30, range 23-34 yrs) had blood collected on 
the day of RUSH immunotherapy(168, 169) and mean 129 days after RUSH (range 41-
188 days) when the maintenance dose was achieved. Concentration of RUSH (w/v) at last 
sample is 1:100. None of these 4 patients have asthma, all skin tested positive to a broad 
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 range of perennial and seasonal allergens. Allergy extracts used in skin tests and 
immunotherapy were as follows: 
Greer Laboratories™. Mold Mixes: alternaria, aspergillus, helminthosporium, 
ormodendrum, penicillium, curvularia, fusarium, mucor, pullularia, rhizopus. Weed 
mixes: cocklebur, lambs quarter, rough pigweed, giant ragweed, short ragweed, sage mix 
(prairie sage, common sagebrush), dock sorrel mix (yellow dock, sheep sorrel), kochia, 
English plantain, nettle. Tree Mixes: eastern sycamore, sweet gum, white mulberry, elm 
mix (American, Chinese), eastern cottonwood, oak mix (black, red, white), sugar maple-
box elder mix, birch mix (black red, white), red cedar, pecan pollen-shagbark hickory 
mix, ash mix (green, white), acacia, mountain cedar, olive. Hollister-Stier ( Bayer)™.   
Dust mites (D. Farinae and D. Pteronyssinus mites), cat hair, dog hair & dander. 
Cockroach mix (American & German). Grass mixes: Kentucky Bluegrass, Orachrd Grass, 
Redtop, Timothy, Sweet Vernal, Meadow Fescue, Perennial Rye, Johnson Grass, 
Bermuda Grass.  
All of these 4 patients had nasal (sneezing, running, blocked), ocular (itching, tear 
flow, redness), ear, headache symptoms prior to immunotherapy and reported symptom 
improvement 1-3 months after immunotherapy. Symptoms intensity was documented as 
0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe. All these patient’s symptoms 
were improved and medication usages were reduced after immunotherapy. The detailed 
information of the patients is summarized in table 3-1.  
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 Table 4-1. Patients information 
 
age  gender  disease    skin    specific    pre-IT           post-IT           interval between 
duration*    test+†     IT†          ID #  score‡      ID #  score‡  microarray (days) 
 
22 M >10     b     b         001      3  - 
58 F >10     a     a         002      3  - 
32 M >10     a     a         004      3  - 
34        F 16     b     b         007      3  - 
23 F 13     a     a         006      3  015 0 167 
30 F >10     a     a         010      3  016 1 41 
31 F >10     b     b         013      3  017 0 119 
34 F 15     c     c         009      3  019 0 188  
  
*disease duration in years; † skin test activity: a= cat, molds, grasses, trees, weeds, b= dust 
mite, cat, dog, molds, grasses, trees, weeds; ‡ symptoms score. c (RAST, 
radioallergosorbent testing)= cat, moulds, grass, tree and weed pollen
IT, immunotherapy 
 
As a control population, we employed eight individuals without a clinical diagnosis and 
no known family history of atopic or autoimmune disease.  Our analysis also included 
samples from our established cohort of autoimmune individuals which has been 
described before (79).  These studies were approved by the Vanderbilt University 
Institutional Review Board. All individuals in diseases groups and control group gave 
written informed consent. 
 
Sample preparation and Microarray procedures. 
Analysis procedures presented here comply with MIAME (minimal information 
about a microarray experiment) guidelines established by the Microarray Gene 
Expression Data Society (www.mged.org).  PBMC were isolated from 20 ml heparinized 
blood on a Ficoll-Hypaque gradient.  All samples were processed within one hour of 
blood collection. Total RNA was isolated with Tri-Reagent (Molecular Research Center. 
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 Inc., Cincinnati OH), 5 µg RNA was reverse-transcribed by reverse transcriptase 
(Superscript II, Invitrogen Corporation, Carlsbad, CA) in the presence of 33P-dCTP.  
Labeled probes were purified using a Bio-Spin 6 Chromatography Column (Bio-Rad 
Laboratories, Inc., Hercules, CA).  Before hybridization, GeneFilters membranes (GF-
211, Research Genetics/Invitrogen Corporation, Carlsbad, CA) were washed in boiled 
0.5% SDS, saturated with 5.0 ml Microhyb solution (HYB125.GF, Research 
Genetics/Invitrogen Corporation, Carlsbad, CA).  Filters were treated with pre-
hybridization reagents (5.0 µg Human Cot-1 DNA and 5.0 µg Poly dA, Invitrogen 
Corporation, Carlsbad, CA) in a hybridization roller tube (Midwest Scientific, St. Louis 
MO) for 2 hours at 42 ºC.  Purified, labeled probes were denatured and added to roller 
bottles containing filters and pre-hybridization solution.  GeneFilters membranes were 
hybridized overnight at 42 ºC. After hybridization, membranes were washed (1st and 2nd 
wash: 2X SSC, 1% SDS at 50 ºC for 20 minutes; 3rd wash: 0.5X SSC, 1% SDS at 55 ºC 
for 15 minutes).  After washing, membranes were exposed to imaging screens for 24 hr 
and the screens were scanned by a phosphorimager (Molecular Dynamics/Amersham 
Biosciences, Piscataway NJ).  Acquired images by the phosphorimager were loaded into 
Pathways 4.0 software (Research Genetics/Invitrogen Corporation, Carlsbad, CA).  The 
relative intensity of each spot on the membrane was determined and the microarray 
dataset was subjected to further analysis using the different analytical platforms. 
Microarray data have been deposited into GEO database, accession number GSE1964 
and series 1-5 (GSM35074-GSM35142). 
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 Data analysis 
Cluster (version 3.0) (123)and JAVA Treeview(170) software programs were 
used to identify similarities among individual samples.  Datasets were analyzed using 
hierarchical clustering algorithms.  As a separate approach, we treated expression levels 
of individual genes from the microarray datasets as separate variables.  We calculated 
averages and standard deviations.  Because of its familiarity, we used the Student's two-
tailed, unpaired t-test to determine statistical significance, P value < 0.05. 
 
Biological process categorization by gene ontology 
EASE: the Expression Analysis Systemic Explorer  
(http://david.niaid.nih.gov/david/ease.htm, EASE version 2.0) was used to search for 
common biological themes within gene lists generated by our microarray analysis.  EASE 
assigns identified genes to “GO: Biological Process” categories of the Gene Ontology 
Consortium (www.geneontology.org) (139-141) and categories are tested statistically 
(EASE: Fisher’s Exact Test) to identify over-represented categories of identified genes 
within the biological process system. Significant functional categories are those with the 
number of list hits (LH) of at least 2 with a P value (EASE) < 0.05 (Fisher’s Exact Test).  
 
Statistical analysis 
Data were normalized to yield an average intensity of 1.0 for each clone (4132) 
represented on the microarray.  Reproducibility of the method was established by 
performing replicate hybridizations to separate microarrays.  Linear regression analysis 
demonstrated that separate hybridizations yielded R2 values ranging from 0.87 to 0.96.  
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 Different exposure lengths of identical filters also produced high R2 values (0.99). The 
Student's t-test was used to determine statistical significance. 
 
Results 
 
Hierarchical clustering of gene expression profiles 
We selected individuals with allergic rhinitis and performed gene expression 
profiling.  Application of hierarchical clustering to gene expression profiles permitted 
accurate segregation of the allergic rhinitis group from control subjects and autoimmune 
subjects by using the entire microarray dataset that included 4132 genes. We also 
identified 68 over-expressed genes, and 165 under-expressed genes that exhibited a 
greater than 3-fold difference in expression between control individuals and individuals 
with allergic rhinitis (before immunotherapy) (P < 0.05, Student's t-test). Using this 
smaller dataset, we were also able to perfectly segregate the allergic rhinitis group, 
independent of receipt of immunotherapy, from the other groups (Fig. 4-1 A, B, and C). 
These results demonstrate that each individual with allergic rhinitis has a common gene 
expression profile that is distinct from control individuals and individuals with 
autoimmune diseases. The ratio of expression levels (allergic/control) of genes that were 
differentially expressed in individuals with allergic rhinitis (before immunotherapy) 
compared to controls varied from a minimum of -4.64 (log2) to a maximum of 5.36 
(log2).  
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Figure 4-1. Hierarchical clustering of gene expression profiles separates the allergic rhinitis 
group from other groups-control and autoimmune.  Hierarchical clustering of microarray data 
using subjects with allergic rhinitis before (pre-) and after (post-) receipt of immunotherapy and 
age-matched controls (Cont) (A), and subjects with allergic rhinitis and autoimmune disease 
(SLE, RA and ERA (early RA)) (B), and subjects with allergic rhinitis, control subjects and 
subjects with autoimmune disease (C).  the allergic rhinitis group is in the blue square. 
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 Given the small sample size of our base of subjects, we also wanted to use standard 
methods to evaluate if these differences between allergic and control subjects would 
achieve statistical significance.  To do this, we treated the expression level of each gene 
as an individual variable and used, because of its familiarity, the student’s T test to 
determine statistical significance.   We found a number of under-expressed and over-
expressed genes that exhibited a high degree of difference between the two subject 
groups with a high level of statistical significance (Table 4-2). These same genes were 
also identified by the hierarchical clustering methods in the heat maps in figure 4-1.   
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 Table 4-2. Quantitative gene expression differences between the allergic and control 
groups. Results are expressed as the average expression level (control, n=8, allergic, n=8) 
± standard deviation.  P values were determined by the student’s T test. 
 
Gene  Control Allergy  p-value 
 
Under-expressed genes: 
CPNE1  11.5±3.9 0.5±0.2 <0.001 
MARCH-VI 9.2±6.0 0.5±0.2 0.005 
CASP6  9.4±2.1 0.6±0.2 <0.001 
DIPA  7.1±1.8 0.5±0.2 <0.001 
CDKN1B  8.9±2.4 0.6±0.2 <0.001 
BPHL  6.2±2.0 0.5±0.2 <0.001 
SST  8.0±5.8 0.6±0.2 0.009 
EFNB1  7.8±3.9 0.6±0.2 0.001 
RIOK3  5.2±1.0 0.4±0.2 <0.001 
SLC1A5  8.2±4.3 0.7±0.2 0.002 
PON3  6.7±4.0 0.6±0.3 0.003 
GGTLA1  4.5±2.5 0.4±0.2 0.002 
POR  4.1±2.2 0.4±0.2 0.002 
PAR5  5.0±2.3 0.5±0.2 0.001 
LMAN1  4.2±2.8 0.5±0.2 0.006 
RAB7  4.4±2.3 0.5±0.2 0.002 
UBE2I  15.8±12.4 1.8±0.8 0.015 
GNAO1  4.3±2.0 0.5±0.2 0.001 
TAF1C  6.1±2.7 0.7±0.4 0.001 
Over-expressed genes: 
 
RAB6  0.3±0.1 13.3±11.7 0.016 
RPL10  0.5±0.2 4.5±3.0 0.007 
APEH  0.3±0.1 2.4±0.7 <0.001 
CETN1  0.3±0.1 2.2±1.7 0.014 
CD22  0.3±0.1 2.1±0.9 0.001 
ESR1  0.3±0.1 1.7±1.4 0.024 
CD53  0.3±0.1 1.4±0.6 0.001 
MCSP  1.4±0.4 7.8±4.2 0.003 
IL8   0.3±0.1 1.8±0.6 <0.001 
RPML3  0.3±0.1 1.2±0.6 0.003 
PLGL  0.4±0.2 2.0±0.7 0.001 
PDGFB  0.2±0.1 0.9±0.4 0.002 
RGS10  0.3±0.1 1.4±0.6 0.001 
HTR3A  0.3±0.1 1.2±0.5 0.001 
PTP4A1  0.3±0.1 1.2±0.6 0.005 
PROS1  0.2±0.1 0.8±0.1 <0.001 
RPL7A  0.9±0.3 3.5±1.5 0.002 
UTX  0.3±0.1 1.2±0.5 0.002 
SEMA5A  0.2±0.0 0.6±0.2 <0.001 
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 According to recent discussions(171-177), we searched our microarray dataset for 
genes of possible relevance to allergic rhinitis, such as cytokines: IL3, IL4, IL5, IL9, IL10, 
IL12, IL13, GM-CSF; cytokine receptors: IL4R, IL10RA, IL10RB, IL13RA1, IL13RA2; 
chemokines and chemokine receptors; T-bet, GATA3; all the chemokines and chemokine 
receptors; immunoglobulin genes: IgE, IgG, IgA; cell surface markers: CD4, CD8 and etc. 
However, these gene expression levels only exhibit modest differences between allergic 
rhinitis patients and healthy controls, except IL8 and IL15. (GEO database: GSE1964: 
GSM35074-GSM35142) 
Our criteria for a differentially expressed gene is that this gene exhibited a greater 
than 3-fold difference in expression between control individuals and individuals with 
allergic rhinitis (before immunotherapy) with P < 0.05 (Student's t-test). Therefore, 
applying these criteria, the genes I discussed above can not be considered as differentially 
expressed genes. In fact, in a previous report, Benson et al used microarrays to study gene 
expression in nasal biopsies from allergic rhinitis patients, they analyzed genes of these 
cytokines, growth factors and their receptors, but the differences in gene expression 
between patients and controls were generally modest (96).  However, even the gene 
expression difference between allergic patients and healthy controls is modest; it can still 
have a significant effect on pathogenesis of allergic rhinitis.    
We also searched our dataset to identify the changes of these allergy related genes 
before and after immunotherapy, only a few of their expressions are significantly 
changed (P<0.05, student’s T test) after immunotherapy, such as CCL16, CXCL13, 
CCL4, CCL25, CCL7, but the fold changes are less than 2, and TGFβ exhibit a two fold 
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 difference between before and after immunotherapy, however, the P value of the 
statistical calculation for TGFβ between before therapy and after therapy is 0.09. 
In our dataset, several genes that have not been previously associated with atopic 
disease showed markedly different levels of expression between the two groups. These 
included MARCH-VI, CASP6, RAB6, and MAN2A2. 
 
Individual variability in differential gene expression 
We selected the ten most under- and over-expressed genes in the atopic 
population compared to non-atopic control individuals for further analysis and grouped 
control individuals (white bars), atopic individuals before therapy (black bars), and atopic 
individuals after therapy (hatched bars).  We found that each under-expressed gene 
exhibited a similar expression level in each atopic individual independent of therapy (Fig 
4-2 A). P-values for each of these differences in gene expression between the allergic and 
control groups treated as an individual variable (Student’s t-test), ranged between 0.01 
and 0.0001. Over-expressed genes, as a group, exhibited somewhat greater variability in 
the atopic population (Fig. 4-2 B).  
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Figure 4-2. Individual variation in gene expression in allergy. Expression levels of individual 
genes were compared in 8 control individuals (white bars) and 12 allergic rhinitis individuals (8 
pre-therapy, black bars, 4 post-therapy, hatched bars). Under-expressed (A) and over-expressed 
(B) genes were analyzed. 
 
 
Some of the variability in the group of over-expressed genes appeared to reflect 
responses to therapy.  For example, expression levels of HBE1 and MSTP9 were 
relatively high in individuals before immunotherapy but were reduced to control levels 
after immunotherapy. 
 
EASE analysis of differentially expressed genes in individuals with allergic rhinitis 
We performed EASE analysis to categorize the over- and under-expressed genes 
in the allergic rhinitis group.  The Gene Ontology Biological Process categories in which 
over- or under- expressed genes were over-represented by EASE scores (Fisher’s Exact 
Test, P < 0.05) are shown in Table 3-3.  
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 Table 4-3. Biological process categories significantly over-represented by 
differentially expressed genes of individuals with allergic rhinitis 
 
Over-expressed Genes  Under-expressed Genes 
     
Gene Category LH EASE Gene Category             LH EASE 
cellular process 31 0.03  induction of apoptosis  5 0.03  
cell communication 19 0.02  JNK cascade   3 0.01 
signal transduction 15 0.04 activation of JUNK  2 0.01 
response to stress 8 0.04 lipoprotein biosynthesis 2 0.01 
cell motility  5 0.03 cellular morphogenesis 2 0.02 
angiogenesis  3 0.00   lipoprotein metabolism 2 0.02 
cell growth  3 0.02  glycerophospholipids  2 0.03  
chemotaxis  3 0.03  DNA replication  2 0.04 
 
LH: list hits, the number of identified differentially expressed genes within 
the specific category. EASE: Fisher’s Exact Test. 
 
 
The most over-represented categories in the over-expressed gene group included 
inflammatory responses, signal transduction and stress responses. In the under-expressed 
gene group, we surprisingly found that the most over-represented category was the 
biological process of apoptosis and activation of the JNK cascade that is also critical for 
many pathways of apoptosis. 
 
Immunotherapy alters gene expression profiles 
Immunotherapy is a common and effective treatment for atopic disease but its 
precise mode of action is not fully understood. We wanted to determine if 
immunotherapy affects the gene expression profile observed in the PBMC of subjects 
with allergic rhinitis.  To do so, we performed hierarchical clustering analysis of subjects 
with allergic rhinitis pre- and post-immunotherapy using different standard deviations to 
evaluate different numbers of genes in the dataset.  We were unable to perfectly 
discriminate between the pre- and post-immunotherapy groups after filtering the dataset 
 69
 by using 1, 1.5 or 2 standard deviations (447, 228, and 123 genes, respectively) (data not 
shown).  However, by decreasing the standard deviation of the filtering condition we 
were able to include more data for analysis and found that expression levels of 563 genes 
could significantly segregate allergic individuals based upon receipt of immunotherapy 
(P<0.05, Fisher’s Exact Test) (Fig. 4-3 A).  
 
 
Figure 4-3. Immunotherapy alters gene expression profiles of individuals with allergic rhinitis. A. 
Hierarchical clustering analysis was performed with a group of atopic individuals before (Pre-) or 
after (Post-) immunotherapy.  Expression levels of 563 genes accurately segregated the pre- and 
post-immunotherapy groups into separate branches.  B. Genes that change expression levels after 
immunotherapy are shown.  Levels of gene expression for control (white bars) and pre- (black 
bars) and post-immunotherapy (hatched bars) (normalized average expression ± S.D) are shown, 
the changes between control and pre-immunotherapy, and changes between pre-immunotherapy 
and post-immunotherapy are significant (P<0.05, Student’s t-test).  C. As in B, except that genes 
that do not change expression levels after immunotherapy are shown (changes between control 
and pre-immunotherapy are significant, P<0.05, and changes between post-immunotherapy and 
pre-immunotherapy are not statistically significant). 
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 Next, we wanted to determine if immunotherapy resulted in detectable changes in gene 
expression in PBMC of individuals with allergic rhinitis. We searched our microarray 
data set to identify changes in expression levels of specific genes in allergic individuals 
before and after receipt of immunotherapy.  We identified a group of genes whose 
expression levels were high or low in allergic individuals (before immunotherapy, P < 
0.05) compared to controls that partially or completely returned to control levels after 
immunotherapy (Fig. 4-3 B, P < 0.05). In contrast, genes that were under-expressed in 
the allergic group before immunotherapy (P < 0.05) remained under-expressed after 
immunotherapy (Fig. 4-3 C, representative examples). We subjected these 563 
discriminatory genes to EASE analysis as shown in Table 4-4.  
 
Table 4-4. Biological process categories significantly over-
represented in the 563 genes 
 
Gene Category    LH EASE  
 
Response to external stimulus  77 0.005 
Response to biotic stimulus  61 <0.001 
Biosynthesis    58 0.004 
Defense response   56 0.001 
Macromolecule biosynthesis  50 0.002 
Immune response   50 0.004 
Protein biosynthesis   41 0.000 
Cell motibility    26 0.015 
Muscle contraction   14 0.009 
Antigen presentation   8 <0.001 
Ribosome biogenesis and assembly 7 0.002 
Cell cycle checkpoint   7 0.004 
DNA recombination   7 0.034 
Smooth muscle contraction  4 0.029 
Centrosome cycle   3 0.001 
DNA damage response   3 0.012 
 
LH: list hits, the number of identified genes within the 
specific category.  EASE: Fisher’s Exact Test.  
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 The most over-represented category was “response to external stimulus”.  In fact, many 
of the gene ontogeny groups selected by the EASE analysis were groups that are typically 
considered to participate in the innate or adaptive immune response.  These results 
suggest that immunotherapy may alter the activities of these pathways to alleviate the 
symptoms of allergy. 
 
Scoring system to classify atopic disease 
As we have done with autoimmune disease (79, 178) , we determined if we could 
devise a scoring system based upon expression levels of small numbers of genes that 
would classify individuals as allergic and distinguish these individuals from control 
individuals and those with autoimmune disease.  We selected 15 under-expressed genes 
and 5 over-expressed genes that, based upon our analysis of the data sets, appeared to 
have the greatest discriminatory power.  To give each gene equal weight in the scoring 
system, we summed the average expression value in the control (N = 8) and allergic 
group (N=6) for each gene and divided by 2 ((control + allergy)/2).  We inspected 
expression levels of each gene in each sample and assigned it a value of 0 if it was less 
than the average and 1 if it was greater than the average. The maximum possible score 
was 15 or 5 for the under- or over-expressed gene categories, respectively, and the 
minimum possible score was 0 (Fig. 4-4 A).   
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Figure 4-4. Gene expression profiles accurately discriminate allergy from autoimmunity and pre-
therapy from post-therapy.  A. The score (y-axis) is shown for each individual subject analyzed 
from the different populations (x-axis).  We used 15 under-expressed genes (left panel) and 5 
over-expressed genes (right panel) to develop the scoring system.  Numbers of samples (N) for 
each category are shown below the graphs.  The allergy (1) group was used to derive the scoring 
system and the allergy (2) group was used to test the scoring system.  Under-expressed genes: 
MARCH-VI, SST, EFNB1, SLC1A5, GGTLA1, POR, TAF1C, PAR5, RAB7, CARP, MAP3K5, 
GNAO1, LAF4, LILRB2, and TGFBI, over-expressed genes: RPML3, CD53, CD22, APEH, and 
CETN1. B. As in A, we used genes whose expression levels have been corrected after 
immunotherapy to design scoring system. We have “therapy corrected genes group 1”: HBE1, 
PF4, BTG1, GRB7, APEH, NFKBIA, RBL1, and YWHAH. And “therapy corrected genes group 2”: 
UQCR, KCNAB2, MADH4, LAT, CREBBP, PFKL and OGT. 
 
 
For under-expressed genes, the range of scores for non-allergic individuals (control and 
autoimmune) ranged from 8 to 15.  All allergic individuals used to derive the initial 
scoring system achieved a score of 0 in the test.  We also analyzed expression data from 6 
additional allergic individuals who were not included to derive the initial scoring system.  
They also received a score of 0 in the test.  Examination of over-expressed genes yielded 
similar results.  Both groups of allergic individuals received scores of 4-5 while all other 
individuals received scores of 0-1.  All these comparisons yielded high levels of 
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 statistical significance (P ≤ 0.0001).  In addition, no individual was incorrectly assigned 
to or excluded from the allergy population based upon score results. Similarly, we 
designed scoring systems to discriminate the status based upon receipt of immunotherapy. 
We employed two groups of genes whose expression levels were high (group 1) or low 
(group 2) in allergic individuals (before immunotherapy, P < 0.05) compared to controls 
and which partially or completely returned to control levels after immunotherapy.  We 
can clearly discriminate pre- and post-therapy groups: by using group 1 genes, the pre-
therapy group received scores of 3-7, the post-therapy group received scores 0-1; by 
using group 2 genes, the pre-therapy group received scores of 0-2 and the post-therapy 
group received scores of 6-7 (Fig. 4-4 B) 
 
 
Discussion 
Our results indicate that there is a conserved gene expression profile in 
individuals with allergic rhinitis.  In this study, the small sample size may be expected to 
limit our conclusions, especially since statistical methods for microarray analysis are 
oftentimes absent or unfamiliar.  Therefore, we also wanted to evaluate statistical 
significance of the microarray results using more familiar methods.  To do so, we also 
treated each gene as an individual variable and used the student’s T test to determine 
statistical significance.  We found that this approach was sufficient to identify a number 
of genes that were differentially expressed between the control and allergic groups with a 
high degree of statistical significance, even for such a small sample size.  This supports 
the idea that atopic individuals have a conserved gene expression profile in their PBMC.  
Using similar approaches, we have also found a conserved gene expression profile in 
 74
 individuals with autoimmune disease.  As with autoimmune disease, we find that 
expression profiles in all individuals with allergic rhinitis are extremely consistent.   
There is < 5% overlap between these two gene expression profiles.  Taken together, these 
results demonstrate that the two major immune-mediated diseases in the human 
population are associated with two unique gene expression profiles in PBMC.  It is our 
hypothesis that these alterations in gene expression result in alterations in cellular 
functions that confer a liability that an individual will develop atopic or autoimmune 
disease, respectively.   
The source we used for this study is PBMC instead of affected tissues. One of the 
reasons to use PBMC is easy access. Also, surgically removed affected tissues are 
generally only in small size that can not generate enough amount of RNA used for 
microarray study, and the positions to obtain the tissues may generate more variation 
compared to PBMC, because the changes of positions may result in variation of cell 
populations which can cause greater variations in microarray study, since there are 
increases in recruitment of certain inflammatory cells around affected tissues, which can 
contaminate the source for microarray study (179). In contrast, current protocol can 
generate enough RNA from PBMC and also the current protocol for isolating the PBMC 
from the whole blood can greatly decrease the contamination of other source. 
In this study, we also designed scoring systems, based upon levels of expression of 
individual genes, one scoring system can correctly classify individuals as having allergic 
rhinitis and exclude controls and individuals with autoimmune disease from this category, 
similarly, and another system can correctly classify individuals based upon receipt of 
immunotherapy.  We have taken a similar approach to the analysis of autoimmune 
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 disease and find that we can also design a scoring system, based upon expression levels 
of small numbers of genes, which can correctly classify individuals as autoimmune.  
These scoring systems may aid clinicians by offering analyses that can correctly classify 
or exclude an individual from the atopic or autoimmune category and can monitor the 
responses to immunotherapy.  Therefore, predictive tests that absolutely classify 
individuals into these disease categories or monitor their responses to therapy may aid the 
decision making process by the clinicians. 
We have 4 patients who are monitored after immunotherapy, the limited sample 
size is always a issue needed to be handled in microarray study, generally complicated 
statistical methods are applied to validate the results(138), in our study, the hierarchical 
clustering algorithm can significantly separate the post-immunotherapy group from pre-
immunotherapy group (P< 0.05, Fisher’s Exact Test), also the gene expression profile of 
our scoring systems can discriminate the pre- and post-immunotherapy groups, this also 
cross validates our results. 
We used a new computer program, EASE: the Expression Analysis Systemic 
Explorer, to search for common biological themes represented by the genes that are 
differentially expressed in atopy.  EASE assigns the identified genes to biological 
processes based upon the Gene Ontology Consortium and employs statistical methods 
(Fisher’s Exact Test) to identify over-represented biological process categories in a given 
gene list.  We separated our gene lists into two categories, over- and under-expressed 
genes.  The over-expressed gene groups in atopy could be broadly categorized as 
contributing to specific aspects of the innate or adaptive immune response.   Genes in the 
under-expressed group could be broadly categorized as genes that encode proteins 
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 required for apoptosis.   Taken together, the observed alterations in these two groups 
suggest that both chronic activation (over-expressed gene group) and reduced apoptosis 
(under-expressed group) may contribute to the chronicity of allergic rhinitis.  This is 
consistent with the suggestion that reduced apoptosis in inflammatory cells may 
contribute to the chronicity of inflammatory processes (180). Many different pathways 
are involved in apoptosis, including signaling through death receptors (FAS, 
TNFR1(181)), the p53 pathway (182), the Bcl-2 family of genes (183) and the caspase 
cascade of effector proteases (183). In our dataset, CASP6 is under-expressed by about 
20-fold and CASP4 is under-expressed by about 3-fold. Components of other apoptosis 
pathways, such as, FAS, TP53, and BCL2, are not differentially expressed in allergic 
rhinitis PBMC. 
A second goal of microarray-based research in human disease is the identification 
of genes whose expression levels change in response to a therapy.  In this regard, these 
“biomarkers” may provide quantitative measurements that demonstrate whether or not a 
given treatment is having its desired effect.  Measurements of biomarker levels could 
augment clinician and patient assessments of therapeutic effectiveness of a given 
treatment.  Desensitization by immunotherapy is a common effective treatment for 
allergic rhinitis although its precise mechanisms are not fully understood (77).   
The immunological changes associated with immunotherapy have been discussed that 
specific IgE levels decrease and IgG titers often rise, perhaps further inhibiting IgE 
production by neutralizing the antigen and by antibody feedback (74). It is also possible 
that immunotherapy may work by inducing specific T cell tolerance or by changing the 
predominant phenotype of antigen-specific T cells from Th2 to Th1 (75, 76). However, 
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 most of these studies test the production of cytokines or immunoglobulins at proteins 
levels serologically, and it has also been described elsewhere that the Th2 to Th1 shift 
represented by mRNA expression changes of cytokines happened in local nasal but not in 
peripheral blood (184, 185). In our study, we used freshly isolated PBMC to examine the 
transcription levels of the genes that are suspected to have relevance in allergic rhinitis 
such as cytokines, chemokines and etc, these genes only exhibit modest differences at 
transcription levels between pre- and post- immunotherapy. However, our analysis of 
gene expression profiles of PBMC from atopic individuals before and after 
immunotherapy permitted accurate segregation of these two groups (P<0.05, Fisher’s 
Exact Test). Surprisingly, measurement of the contribution of expression levels of a large 
number of genes (> 500) was required to achieve complete segregation of the atopic 
group into pre- and post-therapy sub-groups.  This result implicates that immunotherapy 
can alter the gene expression profile, but the genes that are conventionally considered to 
be related to allergic rhinitis did not exhibit substantial changes upon immunotherapy in 
PBMC. And the allergy signature was a relatively stronger signature imprinted in the 
patients before or after immunotherapy, we have to have more gene expression signals to 
discriminate the gene expression profiles pre-immunotherapy from post-immunotherapy.  
When we looked at changes in expression levels of individual genes, we found that we 
could identify a number of genes whose expression levels were significantly high or low 
in the atopic group compared to the control group and returned to control levels after 
immunotherapy.  These genes are potential biomarkers that may augment the ability of a 
clinician to monitor responses to immunotherapy.  Whether expression levels of these 
same genes would also change in response to other forms of therapy that reduce the 
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 symptoms of allergic rhinitis remains to be determined.  In contrast to these results, 
expression levels of those genes that are low in atopy compared to control do not change 
after immunotherapy.  A future goal of drug discovery may be to try to change expression 
levels of this group of genes, which may provide for novel approaches to treatment of 
these diseases.  Nevertheless, these initial experiments demonstrate that it is feasible to 
use gene expression changes as biomarkers to monitor therapeutic responses to a complex 
disease such as allergic rhinitis. 
We also applied EASE analysis to the group of genes chosen by computer that 
permitted accurate segregation of patients before and after immunotherapy.  The most 
over-represented categories in this gene list may be broadly classified as those that 
contribute to an immune response.  These categories include responses to external stimuli, 
defense responses, immune responses, biosynthesis, cell motility, and antigen 
presentation, all key elements of the innate and acquired immune response.  Taken 
together, these results provide molecular support for the observed clinical role of 
immunotherapy, de-sensitization of the host.  
In conclusion, there is a highly conserved gene expression profile among 
individuals with allergic rhinitis, and immunotherapy alters this gene expression profile.  
Knowledge of these gene lists and the changes following immunotherapy may identify 
potential therapeutic targets and potential biomarkers that may be used to monitor 
therapeutic responses.  Both of these may contribute to better care of patients with atopic 
diseases. 
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 CHAPTER V 
 
PREDICTION OF DISEASE SEVERITY IN PATIENTS WITH EARLY 
RHEUMATOID ARTHRITIS 
 
 
Abstract 
 A group of 17 patients with early rheumatoid arthritis (1 ± 0.2 years disease 
duration) was evaluated at baseline for gene expression profiles.  Disease status in these 
patients was re-evaluated after a mean follow-up of 5 years using an index that combined 
pain, global and MHAQ scores.  Baseline gene expression values were analyzed using 
unsupervised and supervised computer algorithms to identify “predictor genes” whose 
combined expression levels correlated with the follow-up disease severity score. Support 
vector machines (SVM) were used to validate the reliability of these predictor genes. The 
unsupervised clustering algorithms separated patients with early rheumatoid arthritis into 
two branches.   The only significant difference between these two groups was the disease 
severity score; demographic variables and medication use was not different between the 
two groups.  Supervised significance of microarray (SAM) analysis identified 6 predictor 
genes of future disease severity. These results were confirmed using SVM to perform 
leave-one out cross validation. Our results indicate that peripheral blood gene expression 
profiles may be a useful tool to predict future disease severity in patients with early 
rheumatoid arthritis.  
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 Introduction 
Rheumatoid arthritis (RA) is a chronic, inflammatory joint disease with 
autoimmune features. Substantial evidence suggests that early intervention in individuals 
with RA results in improved control of disease activity, decreased joint damage and 
fewer extraarticular manifestations (186-188).  Early RA patients may benefit from early 
aggressive therapies, such as new biologic agents that block the activity of TNF-α 
(Tumor Necrosis Factor alpha), which control disease activity and joint destruction (189, 
190).  However, these biologic agents are generally expensive and up to 30% of RA 
patients have incomplete responses (191, 192). In addition, these drugs can have 
significant side effects including increases in severe infections and other autoimmune 
manifestations. In the approximately 30% of early RA patients who do not develop any 
erosion(192), treatment with TNF blockers may not be necessary, and other drugs such as 
methotrexate may be sufficient. These clinical issues highlight the need for new 
approaches that would permit individualization of therapy for patients with early RA 
including development of additional prognostic markers. 
 Current prognostic methods for RA are generally based on the integrated use of 
information derived from patient self-assessment questionnaires, the physical 
examination, routine laboratory studies such as ESR (erythrocyte sedimentation rate) and 
CRP (C-Reactive Protein) and radiographic findings.  Titer of rheumatoid factor and anti-
CCP (antibodies to Cyclic Citrullinated Peptides), imaging methods, including 
conventional X-rays, ultrasound and magnetic resonance, genetic markers, such as HLA-
DRB1 gene alleles, have also been employed (193-197).  Most diagnostic methods are 
dependent on the diagnostic tests that are evaluated. This may result in circularity and 
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 overestimation of the diagnostic properties of the tests (198-200).  Considering the 
prevalence of rheumatoid arthritis, which is estimated as 1% of the US population 
(NIAMS, National Institute of Arthritis and Musculoskeletal and Skin Diseases 2004), 
even a small increase in the accuracy of disease severity prediction has the potential to 
benefit a substantial number of RA patients.  
 Microarrays provide a powerful tool to screen expression levels of thousands of 
genes in a single sample. We and others have used this approach to identify gene 
expression signatures in peripheral blood mononuclear cells (PBMCs) of individuals with 
autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), multiple sclerosis, and type I diabetes mellitus (79, 89-91, 149). We also have 
described a unique gene expression signature that distinguishes patients with early RA 
(ERA) from those with more established disease (80). The objective of the present study 
was to determine if gene expression signatures collected early in the course of RA could 
predict future disease severity.  
 
Materials and methods 
 
Patients 
The 17 patients used for this study were included in a previous report detailing 
results of the initial microarray analyses (201).  Follow-up clinical information was 
obtained by one of the investigators (T.S.) as part of ongoing longitudinal investigations.   
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 The mean (S.E.M.) disease duration for these patients at the time of the initial microarray 
screening was 1 ± 0.2 year.  Clinical course was evaluated after a mean (range) of 5.0 
(1.5-7.4) years.   
Self-assessment evaluations collected in the follow-up analysis included 100 mm 
visual analog scales for pain and global assessment and a modified health assessment 
questionnaire (re-coded MHAQ).  Each of these measures was converted to an indexed 
score. “Pain” and “Global”: 0= 0-9, 1= 10-29, 2= 30-59, 3= ≥60; “Re-coded MHAQ”: 0= 
0, 1= 0.13-0.25, 2= 0.38-0.50, 3= 0.63-1.0, 4= >1.0.  An overall composite index score 
was then calculated as a sum of the three score components.  The overall disease score 
had a possible range of 0-10, with scores of 0-3 considered mild and scores of 4-10 
classified as severe(202).   
This study was approved by the Vanderbilt University Institutional Review Board. 
All individuals participate in this study gave written informed consent. 
 
Sample preparation and microarray procedures 
PBMC were isolated from 20 ml heparinized blood on a Ficoll-Hypaque gradient.  
All samples were processed within 2-4 hours of blood collection. Total RNA was isolated 
with Tri-Reagent (Molecular Research Center. Inc., Cincinnati OH) and 5 µg RNA was 
used to prepare cDNA with reverse transcriptase (Superscript II, Invitrogen Corporation, 
Carlsbad, CA) in the presence of 33P-dCTP.  Labeled probes were purified using a Bio-
Spin 6 Chromatography Column (Bio-Rad Laboratories, Inc., Hercules, CA).  Before 
hybridization, GeneFilters membranes (GF-211, Research Genetics/Invitrogen 
Corporation, Carlsbad, CA) were washed in boiled 0.5% SDS, saturated with 5.0 ml 
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 Microhyb solution (HYB125.GF, Research Genetics/Invitrogen Corporation, Carlsbad, 
CA).  Filters were treated with pre-hybridization reagents (5.0 µg Human Cot-1 DNA and 
5.0 µg Poly dA, Invitrogen Corporation, Carlsbad, CA) in a hybridization roller tube 
(Midwest Scientific, St. Louis MO) for 2 hours at 42 ºC.  Purified, labeled probes were 
denatured and added to roller bottles containing filters and pre-hybridization solution.  
GeneFilters membranes were hybridized overnight at 42 ºC. After hybridization, 
membranes were washed three times, exposed to imaging screens for 24 hr and screens 
were scanned by a phosphorimager (Molecular Dynamics/Amersham Biosciences, 
Piscataway NJ).  Acquired images were loaded into Pathways 4.0 software (Research 
Genetics/Invitrogen Corporation, Carlsbad, CA).  The relative intensity of each spot on 
the membrane was determined and the microarray dataset was subjected to further 
analysis using the different analytical platforms. Data were normalized to yield an 
average intensity of 1.0 for each clone (4133) represented on the microarray. 
Reproducibility of the method was established by performing replicate hybridizations to 
separate microarrays (79).  Original microarray data have been deposited into GEO 
database; accession number GSE1964 (GSM35124-GSM35142).   
 
Data analysis 
Cluster (version 3.0) (123) and TIGR microarray software MultiExperiment 
Viewer (MEV) (130) were used to identify significant genes that can discriminate 
patients according to their future disease severity. The following data analysis modules of 
MEV were used to perform further analyses: HCL (hierarchical clustering), ST (support 
tree clustering), SVM (support vector machines) and PCA (principal components 
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 analysis).  Detailed descriptions of the applications of these programs to the analysis are 
provided in the results section.  Analysis procedures presented here comply with MIAME 
(minimal information about a microarray experiment) guidelines established by the 
Microarray Gene Expression Data Society (www.mged.org).  Clinical variables are 
shown as mean ± S.E.M.  Statistical analyses of the clinical data were carried out using 
Fisher’s exact test or Student’s T Test with a P value of <0.05 considered significant.    
 
Results 
 
Clustering analysis of ERA patient gene expression profiles 
We first performed unsupervised hierarchical clustering of gene expression 
profiles of the ERA patients. The algorithm segregated the patient profiles into two major 
groups (Fig. 5-1). 
 
 
Figure 5-1.  Unsupervised hierarchical clustering was applied to the gene expression profile of 
192 genes that passed the filtering condition (SD=2). The patients were separated into two 
Clusters: 1 and 2 as indicated by the red square. 
1 
2 
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 We compared patient clinical features to determine if the patients that segregated into the 
two clusters exhibited any common clinical feature.  We found that age of onset, race, 
gender and RF positivity were not statistically different between individuals in the two 
groups. Medication usages for steroids and DMARDs or their combinations at the time 
when samples were collected were also not statistically different (Table 5-1). 
 
Table 5-1. Clinical Phenotypes Corresponding to Cluster Designations 
 
Phenotype Cluster 1  2  P valuea 
 
Age of onset   61  65  ns 
 
Severity Mild  8  1  0.015
Severe  2  6  
 
Race  Black  0  2  ns 
White  10  5  
 
Gender Female 9  6  ns 
Male  1  1  
 
Rf  Positive 7  4  ns 
Negative 3  3 
 
GLUCOCORTICOIDs and DMARDs 
 
PRED            5/10  5/7  ns 
MTX            9/10  6/7  ns 
HCQ            1/10  2/7  ns 
LEF            1/10  0/7  ns 
ENB            1/10  1/7  ns 
REMIC           0/10  1/7  ns 
PRED+MTX           9/10  6/7  ns 
+HCQ+LEF    
ENB+REMIC           1/10  2/7  ns  
All DMARDs           9/10  6/7  ns  
 
a: the difference of “age of onset” is calculated by students’ T test, the differences 
 of other phenotypes are calculated by Fisher’s exact test.  ns: not significant 
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  The only significant difference was the disease index distribution.  In Cluster 1, 8 of the 
10 patients (80%) were classified as having mild disease while in Cluster 2, only 1 of 6 
(17%) was in the mild class (P=0.015). 
 
Significance analysis of microarray (SAM) 
The supervised method- Significance Analysis of Microarray (SAM) was used to 
identify genes that were differentially expressed according to their disease severity (Fig. 
5-2 A).  To do this, we divided patients into a severe disease group and a mild disease 
group according to their clinical evaluation (see Patients section) and performed SAM 
analysis with the false discovery rate set to zero.  Under these stringent conditions, 6 
genes were identified. We then performed unsupervised support tree clustering using 
expression levels of these 6 genes (Jackknife algorithm re-sampling by 1000 
permutations).  
 
 
Figure 5-2. Support tree hierarchical clustering was applied to the six predictor genes expression 
profile among 17 patients. A. Jackknife re-sampling was used with permutation 1000 times. The 
color codes correspond to a given level of support. B. Table shows that branch 1 and 2 are 
significantly separated according to their disease severity (P=0.0004, Fisher’s Exact Test). 
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 As shown in Figure 5-2A, two major branches were derived. Patients separated into two 
groups by their future disease severity.  Branch 1 contained 10 patients, and only 1 of 
these was in the severe group while Branch 2 had 7 patients, all of whom were classified 
as severe (P=0.0004, Fisher’s exact test) (Fig 5-2 B). This analysis classified each patient 
according to the clinical evaluation with the exception of patient 21.  According to the 
clinical evaluation, patient 21 should be in the severe group.   However, the clustering 
results grouped this patient into the mild group. 
  
Leave one out cross validation of support vector machines (SVM) 
We next wanted to validate that the 6 identified genes were predictors of future 
disease severity. Unfortunately, we did not have a new early RA patient group to use for 
validation. As an alternative, we used SVM to cross validate the predictors. SVM uses 
kernel function to search a hyperplane in multi-dimensional space that maximizes the 
distance of training samples to the plane from either side and then classifies the test 
samples based on their orientation to the hyperplane (28). We used leave one out cross 
validation (LOOCV) to validate predictor genes. LOOCV analysis employs SVM to 
perform multiple permutations. At every permutation, one of the samples is removed and 
the remaining samples are used as predictors to re-classify the removed sample.  
 Figure 5-3 shows the results of LOOCV of SVM analysis.  We first assigned 
numbers to each patient according to their disease severity: “1” = “severe” and “-1” = 
“mild” based upon their clinical evaluation.  The LOOCV analysis reclassified patient 21 
from the “severe” group to the “mild” group but kept all the other classifications the same.  
In panel II, we assigned the scores according to our clustering results.  Here patient 21 
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 was given a score of “-1”.  The LOOCV analysis maintained the original classification of 
“-1” for patient 21 as well as the classification of remaining patients.  In order to further 
confirm our classification by the 6 genes we changed patient 1’s score from “1” to “-1”, 
and patient 21’s score from “1” to “-1”.  After LOOCV analysis, patient 1’s score was 
corrected to “1” but patient 21’s score remained “-1” (Fig.5-3, panel III).  Next, we 
changed patient 1’s score to “-1” and left the patient 21’s score “1” or unchanged.  After 
LOOCV analysis, patient 1’s score was corrected to “1” and patient 21’s score was 
corrected to “-1” (Fig.5-3, panel IV).   
 
 
 
Figure 5-3.  LOOCV of Support Vector Machines. Leave one out cross validation of support 
vector machines was used to validate our original testing of patients. The scores of disease 
severity are assigned to two groups: severe=1, mild=-1. “Clinc Eval” column shows scores 
assigned to each patient according to clinical evaluation index (see patients and methods); “Init 
Class” column shows scores used as initial classification for SVM; “Class” column shows scores 
assigned to each patient after cross validation. 
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 Taken together, the above LOOCV analysis supports the results from the clustering 
analysis, indicating that the 6 genes may be appropriate candidates as predictors of future 
disease severity in early rheumatoid arthritis patients. 
 
Principal components analysis of 6-predictor gene expression profiles 
By using SAM analysis, we identified 6 genes as predictors of future disease 
severity in ERA patients. After unsupervised clustering (support tree), we classified the 
patients into two groups, a severe group and a mild group, except for patient 21. 
Therefore, we used Principal Component Analysis (PCA) to examine the clusters by 
using the 6 gene expression profiles.  PCA projected all the patients into a 3 dimensional 
space according to their 6 genes expression profiles (Fig. 5-4 A).  The severe group (red 
spheres) and mild group (green spheres) were separated into two polar positions.  Next, 
we projected all the patients onto a two dimensional plane (X, Y) (Fig. 5-4 B).   
 
 
 
Figure 5-4. PCA validation of classification by 6 predicator genes. A, three-dimensional 
projection of 17 patients by expression levels of 6 predictor genes. Green spheres represent the 
mild group. Red spheres represent the severe group. B. 2-dimensional projection of 17 patients by 
gene expression levels of 6 predictor genes onto (X, Y) plane. Dashed line was drawn between 
severe group and mild group of ERA patients. Green squares represent the mild group. Red 
squares represent the severe group. 
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 Patients were separated into two areas by the dashed line.  Patient 21 aligned very close 
to the mild group, which may be the reason why we cannot classify this subject in 
accordance with the clinical evaluation. 
 
The 6-predictor genes 
Each of the 6-predictor genes: MPG, RHOA, CUTL1, HLA-DQB1, PIK3CD, and 
CKS1B, was over-expressed in the severe patient group compared to the mild patient 
group (Fig. 5-5 A).   
 
 
 
Figure 5-5.  Average gene expression intensity in severe group and mild group is shown by bar 
graph in A for the 6 predictor genes. The value represented is the mean ± standard deviation in 
each group.  Each gene’s gene bank accession number, symbol, name and average expression 
intensity in severe and mild group are shown in B, students’ T test was used to measure the 
significance of difference. 
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 Although the average difference in transcript levels of each gene was < 2-fold between 
the two groups, the difference in transcript levels of each gene achieved a high level of 
statistical significance (P < 0.005) (Fig. 5-5 B).   
 
Discussion 
Disease-modifying therapy early in the course of RA can lead to improved disease 
control and decreased joint damage (203, 204).  However, the uncertain course of RA in 
some patients coupled with the adverse effects and high cost of newer therapies make 
decisions regarding treatment strategies complex.  About 30% of early RA patients will 
not develop severe disease and a small number may even undergo remission without 
treatment (191, 192).  The current prognostic factors are relatively powerful tools, 
including measurement of HAQ scores, autoantibody levels and genetic markers.  
However, the prognostic sensitivity of the combined tests is in range of 80%-90% which 
is not sufficient to predict outcome in an individual patient (192, 205-208).  
In the present study, we identified a combination of 6 expressed genes that 
correlated with clinical course in RA patients.  We can achieve > 94% (16/17) accuracy 
of prediction of future disease severity if our clinical follow up assessment is 100% 
accurate.  We propose that addition of this analysis to other measures, such as HAQ score, 
HLA genotyping, and rheumatoid factor may be useful to predict future disease severity 
in early RA patients.   This information may then be useful for making decisions about 
therapies.  
 In our study, we did not have an independent population to validate our predictor 
genes and considering the small sample size of the data set, as an alternative, we applied 
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 LOOCV.  LOOCV has been widely used to validate classification and prediction models 
of disease and is considered to be statistically sufficient validation (102, 109, 138).  We 
found that our results from LOOCV were consistent with our clustering analysis.  
However, independent validation is still the gold standard to verify our results. 
The difference in the expression pattern of the 6-predictor genes is remarkably 
consistent in both the severe and mild patient group.  Interestingly, MPG protein levels 
are know to be increased in patients with RA compared to controls (209).  Most analyses 
of HLA-DR and HLA-DQ have focused on genetic polymorphisms rather than differences 
in expression levels (197, 210).  In addition to these sequence polymorphisms, transcript 
levels of HLA-DRB1 are also elevated in RA (211).  Our results confirm that transcript 
levels of HLA-DQB1 are elevated in RA and demonstrate that they also help discriminate 
mild from severe disease.  We did not find direct evidence to link RHOA, CUTL1, 
PIK3CD, and CKS1B with the disease activity of rheumatoid arthritis. However, proteins 
encoded by these genes are involved in critical cellular functions such as signal 
transduction, regulation of gene expression, and cell cycle progression and may have 
unknown effects on disease course of RA.  
 Our 6-predictor gene system accurately discriminates the severe group and mild 
group achieving more than 94% accuracy. These results suggest that it is possible to 
predict future disease severity using this type of approach.  At the time of sampling, 
between sampling and clinical follow-up, and at the time of clinical follow-up, all 
patients were on some type of anti-rheumatic therapy.  Clinically, RA is a very 
heterogeneous disease and our system may discriminate between individuals who will 
develop aggressive or mild disease.  Alternatively, our system may discriminate between 
 93
 individuals who exhibit good responses to anti-rheumatic therapies and therefore develop 
mild disease and those patients who exhibit poor responses to anti-rheumatic therapies 
and therefore develop severe disease.  Other unrecognized co-variables may also 
contribute to the precise mechanism that allows expression levels of the 6-predictor gene 
set to predict if an individual will develop severe or mild disease.    
 In summary, we identified 6 genes whose expression levels in ERA predict future 
disease severity.  By using LOOCV and PCA, we validated this classification.  Taken 
together, these results suggest it may be possible to use gene expression profiling in ERA 
to predict future disease severity.   
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 CHAPTER VI 
 
STUDY OF MURINE MODELS OF AUTOIMMUNE DISEASE BY GENE 
EXPRESSION PROFILING 
 
 
Abstract 
A general view is that critical genes involved in biological pathways are highly 
conserved among species.  In order to understand human autoimmune diseases, a great 
deal of effort has been devoted to the study of murine models that mirror many 
pathologic properties observed in a given human disease.  In our study, we first identified 
a specific gene expression profile of T lymphocytes in NOD mice, in which a deregulated 
system was identified. This feature of lymphocytes in NOD mice may explain their 
susceptibility to apoptosis compared to non-diabetic C57BL6 or NOD.H2h4 mice and it 
may represent the underlying mechanism causing lymphopenia in NOD mice believed to 
contribute to onset of autoimmunity.  
Second, since we found that lymphocytes from humans with different 
autoimmune diseases all carry a common conserved gene expression profile, we wanted 
to determine if lymphocytes from common murine models of autoimmune disease carried 
a gene expression profile similar to the human profile and if both IDDM and SLE mouse 
models carried a shared gene expression profile.  We identified numerous differentially 
expressed genes in the autoimmune strains compared to non-autoimmune strains.  
However, we found very little overlap in the gene expression profile between human 
autoimmune disease and murine models of autoimmune disease and between different 
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 murine autoimmune models. Our research further demonstrates that murine models of 
autoimmunity do not perfectly match human autoimmune diseases. 
 
Part I: Deregulated stress system of lymphocytes in NOD mice measured by gene 
expression profiling 
 
Introduction 
Autoimmune diseases are believed to arise from complex interactions between 
genetic and environmental factors(1, 142). In order to understand the pathogenesis of 
autoimmune diseases, investigators have devoted considerable effort to the study of 
animal models of autoimmune disease.  For diabetes, these include diabetic prone BB rats 
and non-obese diabetic (NOD) mice that spontaneously develop an insulin-dependent 
diabetes mellitus (IDDM)-like syndrome (54, 55, 212, 213). A profound lymphopenia has 
been reported to lead to diabetes in BB rats (20, 21), and intrinsic defects in lymphopenia 
and homeostatic expansion in NOD mice may contribute to establish autoimmunity (17). 
In this study, we try to determine if apoptosis defects exist in lymphocytes of NOD mice, 
which could represent an underlying mechanism leading to lymphopenia.  We also 
wanted to determine if we could find alterations in transcript levels of specific genes that 
may contribute to alterations in sensitivity to apoptosis.  We revealed that NOD mice had 
a higher apoptotic population of lymphocytes than that of B6 mice or the non-diabetic 
congenic strain, NOD.H2h4, in vivo.  NOD T cells are also more susceptible to apoptosis-
inducing stimuli than B6 or NOD.H2h4 T cells. Gene expression profiling analysis 
identified a set of genes with a unique expression profile in NOD T cells. The apoptosis 
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 prone characteristic of this gene expression profile was identified by the over-represented 
biological categories, especially the de-regulated heat shock proteins. Therefore, this 
specific expression pattern of these genes may contribute to establishing susceptibility to 
apoptosis that may increase the likelihood of developing autoimmune diabetes. 
 
Materials and methods 
Mice: NOD, C57BL/6 and B6.Idd1,5 female mice were obtained from Jackson 
Labs (Bar Harbor, ME). Procedures and care of animals were in accordance with 
Vanderbilt University guidelines provided by the Institutional Animal Care and Use 
Committee.  B6.Idd1,5 is a double congenic strain that contains the NOD MHC Idd1and 
NOD Idd5 loci on the C57BL/6 background.  This strain develops periinsulitis, but 
insulitis is extremely rare (Jackson Labs Mice Database). The experiments were 
performed by using the female, age matched mice at age of 12 weeks old. 
Reagents: complete RPMI 1640 medium supplemented with 10% FBS (HyClone 
Laboratories, Logan, UT), 100 U/ml of penicillin, 100 μg/ml of streptomycin, 2mM L-
glutamine, and 0.05 mM 2-ME (J. T. Baker, Phillipsburg, NJ) was used for cell culture.  
The mAbs used in this study were purified from tissue culture fluids of hybridoma cells 
obtained from American Type Culture Collection (Manassas, VA): anti-I-A (10-3.6.2, 
specific for I-A g7, k, r, f, or s haplotypes; Y3P, specific for I-A b, f, p, q, r, s, u and v 
haplotypes).  BioMag® goat anti-mouse IgG coated magnetic beads were obtained from 
QIAGEN (Valencia, CA).  Tri Reagent was obtained from Molecular Research Center, 
Inc (Cincinnati, OH).  Superscript II transcriptase was obtained from Invitrogen 
Corporation (Carlsbad, CA). Annexin-V PE Apoptosis Detection Kit I, FITC-conjugated 
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 anti-CD3 antibody and APC-conjugated anti-CD19 antibody were purchased from BD 
Pharmingen (San Diego, CA 92121). PCR purification kits were obtained from QIAGEN.  
CMTTM hybridization chambers were obtained from CORNING (Corning, NY). Cy5, 
Cy3 and other reagents used for cDNA labeling and hybridization were obtained from 
VMSR (Vanderbilt Microarray Shared Resource).  NIA mouse15K microarray chips 
were made by VMSR.  
NIA Mouse 15K cDNA clone set: the NIA mouse 15K cDNA clone set is a 
15,247-element clone set.  The 15K clone set was developed at the National Institutes of 
Aging (NIA) and has been sequence verified from both the 5’ and 3’ termini.  
Approximately 15,000 unique cDNA clones were derived from 52,374 ESTs from pre- 
and periimplantation embryos, E12.5 female gonad/mesonephros, and new born 
ovary(214).  Every cDNA clone is assigned a unique clone ID in the mouse 15K NIA 
clone set.  
CD3+ T cells purification: CD3+ T lymphocytes were purified from spleen by 
negative selection.  Red blood cells were removed by hypotonic lysis.  I-A expressing 
cells were removed by incubation with anti-I-A antibody (10-3.6.2 for NOD and 
B6.Idd1,5; Y3P for C57BL/6) for 30 min at 0◦-4◦C and with goat anti-mouse IgG coated 
magnetic beads at room temperature for 30 min.  A magnetic column removed cells 
bound to beads.  Average purity of CD3+ T cells was approximately 90-95% as 
determined by flow cytometry.   
Total RNA isolation: Tri Reagent was used to isolate total RNA according to the 
manufacture’s protocol.  We pooled total RNA from purified T cells of 2-3 mice for each 
microarray experiment.  This provided us with sufficient total RNA and decreased bias 
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 due to biological variation.  We used 5×107 cells to isolate total RNA for each group 
(experimental and control) for each microarray experiment.  
cDNA labeling, microarray hybridization, and data analysis: Labeled cDNA was 
prepared from 10 μg of total RNA.  RNA was transcribed into fluorescently labeled 
cDNA using an anchored oligo-dT primer (dT20MN), unlabeled dNTPs, superscript II 
reverse transcriptase, and dCTP labeled with one of the two fluorophores, Cy5 or Cy3, 
according to the standard protocol of VMSR.  The Cy5 and Cy3 labeled cDNAs were 
combined, purified together, and dissolved in 2x hybridization buffer (50% formamide, 
10 × SSC and 0.2% SDS). Microarray slides were prehybridized in 1% BSA, 5 × SSC, 
and 0.1% SDS at 55°C for 45 min.  After prehybridization, slides were rinsed 5 times in 
MilliQ water, 1 time in isopropanol, and allowed to air dry. Combined samples were 
placed on the prehybridized slides and covered with lifterslips.  Microarray slides were 
hybridized at 42°C for 14-16 hours in a humidified hybridization chamber.  After 
hybridization, the lifterslips were removed and microarray slides were washed at room 
temperature with serial 5-min washes with 2 × SSC, 0.1%SDS, 1 × SSC, and 0.1 × SSC 
and dried by centrifugation at 50 × g for 5 min. Microarray slides were scanned using a 
GenePix® 4000B scanner (Axon Instrument Inc., Union City, CA). Image files were 
analyzed with GenePix® Pro 3.0 software (Axon Instrument Inc., Union City, CA). The 
software package was used to identify individual clones from the microarray image and 
to calculate signal intensity values. Ratios (fluorescent intensity of experimental sample/ 
fluorescent intensity of control sample) from the two channels (red: Cy5, green: Cy3) 
represent the fold change in gene expression levels between the two samples. Each 
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 microarray was performed at least twice and results were averaged.  Microarray original 
data were deposited into GEO database: GSE2524 
Definition of differentially expressed genes-DEGs: DEGs are defined as a clone 
that exhibited a greater than 3-fold difference in expression between subject strains and 
reference strains with a P < 0.05 (the Students’ T test). 
Biological process categorization by gene ontology: EASE: the Expression 
Analysis Systemic Explorer (http://david.niaid.nih.gov/david/ease.htm, EASE version 2.0) 
was used to search for common biological themes within gene lists generated by our 
microarray analysis.  EASE assigns identified genes to “GO: Biological Process” 
categories from the Gene Ontology Consortium (www.geneontology.org) (139-141). 
Significant over-represented categories are those with the number of list hits (LH) of at 
least 2 with a P < 0.05 (Fisher’s Exact Test).  
Reciprocal bone marrow transfer experiment: Two MHC class II matched strains: 
NOD and B6.Idd1,5 were used. Recipient mice were irradiated by gamma irradiation at a 
lethal dose of 10 Gy and received donor bone marrow (1 x 107 cells) by I.V. injection at 
the base of the tail.  T cells were harvested 6 weeks after bone marrow transfers and used 
for microarray analysis. 
Endogenous and stimuli-induced apoptosis:  To induce apoptosis dependent upon 
DNA strand breaks, spleen cells were exposed to a total dose of 2 Gy of gamma 
irradiation using a Marker 1 Irradiator (J.L.Shepherd & Associates, Glendale, Calif.) at a 
dose rate of 1.897 Gy/min at room temperature. To induce a heat shock response, cells 
were transferred into 5 ml medium (2×106/ml) and incubated at 42 ºC for 30 min. After 
16 hours of culture at 37 ºC, cells were harvested.  Freshly isolated and cultured cells 
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 were stained with PE-conjugated Annexin-V, FITC-conjugated anti-CD3 antibody and 
APC-conjugated anti-CD19 antibody according to the manufacture’s protocol. Flow 
cytometry data were collected on a FACScan using CellQuest Software (BD Bioscience, 
San Jose, CA) and analyzed by WinMDI software packages (provided by J. Trotter, The 
Scripps Research Institute, La Jolla, CA). 
Reverse transcription and Real-time PCR analysis: Total RNA was prepared 
using Tri-Reagent and used for first strand synthesis with Superscript III First-Strand 
Synthesis System for RT-PCR (Invitrogen Corporation, Carlsbad, CA). 2 g of the total 
RNA of NOD and B6 mice was reverse-transcribed. In order to evaluate the transcribed 
Hsp105 gene expression, we performed TaqMan RT-PCR using ICycler IQ Multicolor 
Real-time PCR Detection System (Bio-Rad laboratories, Inc., Hercules, CA). Reactions 
were performed in triplicate. TaqMan reactions were setup in 96-well PCR plates (Bio-
Rad laboratories, Inc., Hercules, CA 94547) according to manufacturer’s protocols. For 
each reaction, added 22.5 µl cDNA template (50ng RNA used), 25 µl 2X TaqMan 
Universal Master Mix (Applied Biosystems, Branchburg, NJ) and 2.5 µl 20X TaqMan 
Gene Expression Assay. Running the plate by default PCR thermal conditions according 
to manufacturer’s protocol (Applied Biosystems, TaqMan Gene Expression Assay 
Protocol 4333458B).  TaqMan Gene Expression Assays: Mm00607939_s1, Actb; 
Mm00442864_m1, Hsp105/Hsp110   (Applied Biosystems, Branchburg, NJ). Changes in 
cycle threshold ( Ct) values of the samples were determined by subtracting the average 
of the triplicate Ct values of the target gene (Hsp105) from the average of the triplicate Ct 
values of the reference gene (ACTB). The relative gene expression levels were 
determined by subtracting the average Ct value of the target from the average Ct 
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 value of the calibrator. The amount of target (expressed as fold change), normalized to an 
endogenous reference and relative to a calibrator, was expressed as 2- Ct (User Bulletin 
#2, Applied Biosystems, Branchburg, NJ). 
Western blot assay: Cell lysates were prepared from purified CD3+ T cells of 
NOD, and B6 mice by incubation in 250 µl RIPA buffer (Tris-HCl: 50 mM, pH 7.4 NP-
40: 1% Na-deoxycholate: 0.25% NaCl: 150 mM EDTA: 1 mM). Protein (80 µg/lane) 
was separated on 10% precast SDS-PAGE gels (Bio-Rad Laboratories, Hercules, CA), 
under reducing conditions and blotted onto Sequi-Blot PVDF membrane (Bio-Rad 
Laboratories, Hercules, CA). Hsp90 α/β and Hsp105 were identified using the rabbit 
polyclonal anti-Hsp90α/β, anti-Hsp105 antibodies (Santa Cruz Biotechnology Inc, Santa 
Cruz, CA), followed by HRP-conjugated bovine anti-rabbit-IgG (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA) as the secondary antibody.  Membranes were 
exposed to ECL plus reagent (Amersham Biosciences UK) according to the 
manufacture’s protocol, developed with a Kodak Image Station 440CF, and analyzed 
using one-dimensional Image Analysis software (Kodak Molecular Imaging System, 
USA). 
 
Results 
 
Apoptosis in NOD T cells 
Lymphopenia in NOD mice may result from increased apoptosis or other 
mechanisms. We used two approaches to explore this hypothesis. First, we determined if 
strain dependent differences in the portion of apoptotic lymphocytes exist, in vivo. We 
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 used Annexin-V staining and flow cytometry to determine the percentage of apoptotic T 
cells and B cells in age-matched female NOD, B6 and NOD.H2h4 mice.  We found a 
larger fraction of apoptotic T cells in NOD compared to B6 and NOD.H2h4 (Figure. 6-1a).  
Interestingly, we also identified a similar pattern in B cells.  The percentage of apoptotic 
B cells was higher in NOD mice than in B6 and NOD.H2h4 mice (Fig. 6-1b).  
 
 
Figure 6-1. Lymphocyte apoptosis, in vivo. Spleen cells were harvested from female age-
matched mice of the indicated strains.  Lymphocytes were stained with FITC-labeled anti-CD3, 
APC-labeled anti-CD19, and PE-labeled annexin V and analyzed by flow cytometry.  Results are 
expressed as the mean ± standard deviation of 6 mice in each group.  (a) % apoptotic T cells, 
NOD vs B6, NOD vs NOD.H2h4: P<0.05 (Students’ T test).  (b) % apoptotic B cells, NOD vs B6, 
NOD vs NOD.H2h4: P<0.05 (Students’ T test). 
 
 
Second, we performed cell culture experiments to determine sensitivity to cell death 
after exposure to stimuli known to induce apoptosis, gamma irradiation and heat shock. 
After 16 hours, cultures were harvested and cells labeled with PE-conjugated Annexin-V 
and FITC-conjugated anti-CD3.  The percentage of apoptotic cells was determined by 
flow cytometry.  We found that NOD T cells were more sensitive to gamma radiation 
induced apoptosis than B6 or NOD.H2h4 T cells (Fig. 6-2a). The rate of apoptosis in 
NOD T cells was 30% higher than in B6 T cells.  
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Figure 6-2. Rate of T cell apoptosis after (a) gamma irradiation induced apoptosis or (b) heat 
shock induced apoptosis, in vitro. T cells were harvested from female age-matched mice of the 
indicated strains and subjected to gamma irradiation or heat shock as outlined in Methods.  After 
16 hr, cultures were harvested, labeled with FITC-labeled anti-CD3 and PE-labeled Annexin V 
and analyzed by flow cytometry.  The ratio represents the % of Annexin-V positive cells in the 
treated group compared to the untreated group. The values represent mean ± standard deviation of 
3 animals in each group. Student’s t-test was used to calculate statistical significance, in (a): NOD 
vs B6, NOD vs NOD.H2h4: P<0.05 (Students’ T test) in (b) NOD vs B6: P<0.05 (Students’ T 
test). 
 
 
We also compared apoptosis between T cells of NOD and B6 mice after heat shock. 
Apoptosis of NOD T cells was almost 40% higher than that of B6 T cells (Fig. 6-2b). 
This suggests that the increased apoptotic fraction observed, in vivo, may reflect an 
intrinsic property of NOD T and B lymphocytes rather than an external property of the 
host environment. 
 
Unique gene expression profiles in NOD T cells 
From the apoptosis assays, we learned that NOD lymphocytes have an apoptosis-
prone characteristic and it may lead to lymphopenia in NOD mice.  Next, we tried to 
search for an underlying mechanism that may explain susceptibility to apoptosis in NOD 
lymphocytes. We used microarrays to attempt to identify differentially expressed genes 
between NOD mice and control strains-B6 mice to determine if these differentially 
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 expressed genes can be candidates to confer a functional liability upon NOD T cells to 
make them more susceptible to apoptosis than B6. We identified 109 differentially 
expressed genes (DEGs) between the two strains. Most DEGs were over-expressed (81 
DEGs) rather than under-expressed (28 DEGs) in NOD T cells.  The level of over-
expression ranged from approximately 3- to 15-fold, the level of under-expression ranged 
from approximately 3- to 6- fold (Fig. 6-3).  
 
 
Figure 6-3.  Gene expression profiles of differentially expressed genes of NOD T cells.  Total 
RNA was isolated from 10-12 week old NOD and C57BL/6 T cells; labeled with Cy5 or Cy3 
dyes and hybridized to the NIA mouse 15K microarray slide. The ratio (log2) (NOD/B6) of 
expression of individual DEGs (○) is shown. 
 
 
This set of genes (NOD DEGs, hereafter) can be viewed as a specific profile of NOD T 
cells.  
 
EASE analysis of NOD DEGs 
NOD DEG expression profiles may result in strain dependent differences in 
functional properties. Therefore, we performed EASE analysis to categorize over- and 
under-expressed genes in NOD DEGs into functional categories that are over-represented 
compared to the entire NOD DEG list (Fisher’s Exact Test, P < 0.05). The most over-
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 represented categories in the over-expressed gene group were apoptosis-inducing genes 
including BNIP3L, PDCD7, and TIA1 (Table 6-1).  
 
Table 6-1. Biologic process categories significantly over-represented (P < 0.05; 
Fisher’s Exact Test) by differentially expressed genes in NOD mice. 
 
Over expressed genes 
 
Gene Category  LH EASE Gene Symbol    
   
apoptosis   3 0.046 Pdcd7; Bnip3l; Tia1 
proton transport  2 0.012 Atp1a1;Atp6v0d1 
chromatin assembly  2 0.019 Nap1l4; Cbx5 
coenzyme,   2 0.021 Atp6v0d1; Alas2 
prosthetic group synthesis 
  
Under expressed genes 
 
Gene Category  LH EASE   Gene Symbol    
   
protein folding  5 0.000   Hsp90α/β;Cct3; Hspa8; Dnajb1 
response to external stimulus 5 0.000   Hsp90α/β; Hsp105;Hspa8; Ly6e 
response to stress  4 0.002   Hsp90α/β; Hsp105;Hspa8 
protein metabolism  6 0.030   Hsp90α/β;Cct3;Hspa8;Dnajb1; Ly6e 
 
LH: list hits, the number of identified differentially expressed genes within the specific 
category. EASE: P value of Fisher’s Exact Test. 
 
 
In the under-expressed gene group, we found that all of the most over-represented 
categories were stress response related heat shock proteins or chaperones, including 
Hsp90α/β and Hsp105.  Both Hsp90 α/β and Hsp105 are known regulators of cellular 
apoptosis and, under certain experimental conditions, will inhibit cell apoptosis (215-218). 
The EASE analysis results suggested that the NOD DEGs are associated with apoptosis 
pathways. 
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 Validation of microarray data 
Next we performed western blotting to determine expression levels of Hsp90α/β and 
Hsp105 proteins in NOD and B6 T cells. Hsp90 protein expression was lower in NOD T 
cells compared to B6 T cells (Fig. 6-4a). Similarly, Hsp105 protein expression was lower 
in NOD compared to B6 T cells (Fig. 6-4b). We also used real-time PCR to measure the 
expression level of Hsp105.  We found it to be higher in B6 than in NOD T cells (mean 
fold changes of 4.4, range 3.5-5.3).  These results confirmed our microarray results. 
 
 
Figure 6-4. Western blot analysis of Hsp90 and Hsp105 protein levels in NOD, B6 T cells. (a) 
Hsp90α/β protein levels in NOD and B6 detected by western blot assay. β-actin was used as 
loading control. The bar graph represents Hsp90 expression normalized to β-actin. (b) Hsp105 
protein expression in NOD and B6 detected by western blot assay. β-actin was used as loading 
control. The bar graph represents Hsp105 expression normalized to β-actin. 
 
 
NOD T cells DEGs are donor- rather than host-dependent in bone marrow transplants 
We performed bone marrow transfer experiments to determine if the unique NOD 
DEG expression profile was dependent upon donor cells of origin or the host 
environment. Splenic T cells were harvested from bone marrow chimeras (“B6toNOD” 
refers to chimeric mice whose donor is B6.Idd1,5 and recipient is NOD; similarly, 
“NODtoB6” refers to bone marrow chimeras whose donor is NOD and recipient is 
B6.Idd1,5). We compared NOD DEG profiles in T cells between NOD mice and 
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 “NODtoB6” mice. We found that most of the DEG expression profile in “NODtoB6” 
mice was similar to that in NOD mice (Fig. 6-5a).  
 
 
Figure 6-5. Gene expression profiles of NOD DEGs developing in different host environments.   
Total RNA was isolated from parental T cells and T cells from recipient mice after adoptive 
transfer: (a) NODtoB6 (donor: NOD mice, recipient: B6.Idd1, 5 mice). (b) B6toNOD (donor: 
B6.Idd1, 5 mice, recipient: NOD mice).   
 
 
However, when we compared the gene expression profiles of DEGs in T cells between 
NOD mice and “B6toNOD” mice, we found that the expression levels of most of the 
DEGs in “B6toNOD” mice were similar to expression levels of B6 T cells (Fig. 6-5b). 
Therefore, these bone marrow transfer experiments clearly support the notion that, at 
least for splenic T cells, the gene expression profile is a strain dependent trait and does 
not vary significantly when T cells develop in a different strain with an identical MHC.  
However, we cannot rule out the possibility that MHC also contributes to the unique gene 
expression profile of T cells. 
 
Association of Gene expression profiles with MHC 
From the bone marrow transplantation experiments, we demonstrated that the 
gene expression profile of NOD T cells seems to be an intrinsic trait rather than a 
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 reflection of the host environment.  Next we performed microarray analysis to compare 
gene expression profiles in T cells from diabetic NOD and the non-diabetic congenic 
strain- NOD.H2h4.  We used the same RNA pool from C57BL/6 T cells for comparison 
and found that the gene expression level of NOD DEGs was greatly altered by the 
exchange of the MHC (Idd1 loci).  Expression levels of NOD DEGS in NOD.H2h4 T 
cells were more like B6 T cells than of NOD T cells (Fig. 6-6).   
 
 
Figure 6-6. Comparison of gene expression profiles of splenic T cells between NOD and 
congenic strain-NOD.H2h4. Expression ratios of NOD DEGs in NOD (O) or NOD.H2h4 (×) T 
cells were compared to C57BL/6 T cells. T cells were hybridized with RNA from C57BL/6 T 
cells to microarray slides containing the 15 K NIA clone set.   
 
 
These results show that, in NOD congenic strains, at least for T cells, replacement of the 
MHC region in NOD can lead to marked changes in gene expression profiles. This 
altered gene expression profile may result in altered functional properties of NOD.H2h4 T 
cells.  
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 Discussion 
In this study, we demonstrated that lymphocytes of NOD mice exhibit a higher 
percentage of apoptotic cells in vivo. Although defects in phagocytosis of apoptotic cells 
by macrophages in NOD mice may contribute to the increase in numbers of apoptotic 
cells (219), in this study, we showed that NOD T cells exhibit greater sensitivity to 
apoptosis-inducing stimuli in cell cultures than those of B6 and NOD.H2h4 strains. Thus 
we propose that increased sensitivity to apoptosis, at least in part, contributes to the 
increased numbers of apoptotic cells observed in vivo.   Our gene expression profiling 
analysis identified a specific gene expression profile for NOD T cells, which implicated 
increased susceptibility to apoptosis as a potential defect in NOD T cells. Therefore, 
enhanced apoptosis in NOD T cells maybe a potential cause for lymphopenia in NOD 
mice. It has been discussed in autoimmune animal models that lymphopenia can be an 
underlying mechanism to generate autoimmune diseases (17, 20, 21). The elevated 
apoptosis of T cells in diabetic BB rats has been described, and in peripheral lymphoid 
organs of diabetic prone BB rats have severe T cell lymphopenia (21). The lymphopenia 
in NOD T cells induced compensatory homeostatic proliferation may generate 
autoimmunity (17). 
Given our results, it is difficult to conclude that a difference in expression of a single 
gene or protein in NOD lymphocytes accounts for the observed differences in 
susceptibility to apoptosis.  Rather, we find that a collection of genes and proteins that 
have known roles in inducing or preventing apoptosis are differentially expressed in 
NOD T cells, this specific gene expression profile may represent the specific trait of 
NOD T cells. Among these genes, one category is apoptosis-inducing genes and these 
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 genes are over-expressed and include Bnip3l and Pdcd7 (220, 221). In under expressed 
genes, the most over-represented category is heat shock proteins, how the heat shock 
proteins regulate the apoptosis has been reviewed(222). The heat shock protein Hsp90, 
one of the most over-represented genes in under-expressed NOD DEGs, is also an 
important regulator of apoptosis (215-217, 223, 224). More interesting, an inhibitor of 
apoptosis (IAP) family member-survivin(225), which was recently reported to be 
required for both proliferation and inhibition of apoptosis of expanding T cells(226), is 
also regulated by Hsp90 and global suppression of Hsp90 results in proteasomal 
degradation of survivin and apoptosis(227).  It has also been suggested that Hsp105 
protects microtubules and has anti-apoptotic function(228). Therefore, these proteins 
probably contribute to a generalized increase in sensitivity to apoptosis as we observed in 
apoptotic cells measurement in vivo and in vitro cell culture assay, which in turn, may 
contribute to the observed lymphopenia in NOD (17).   
Bone marrow transplantation experiments revealed that the gene expression profile 
of T cells in NOD is probably an independent property of NOD T cells, not varying 
according to different host environment.  Non-diabetic congenic strain NOD.H2h4 exhibit 
similar apoptosis pattern in vivo or in vitro as that of B6 mice, the expression of NOD 
DEGs in NOD.H2h4 also show the similar pattern as that of B6 mice. All these evidences 
suggested that the specific gene expression profile of T cells in NOD mice is an 
independent property that may contribute to establish the elevated apoptosis in NOD 
lymphocytes. In addition, the process of lymphopenia leading to autoimmunity may map 
to Idd3 locus(17), however, the congenic mice-NOD.H2h4 with altered Idd1 loci did not 
exhibit apoptosis prone characteristic, and NOD DEGs gene expression in NOD.H2h4 
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 was also modulated to control level. These results suggested that Idd1 loci may also 
contribute to establish the susceptibility to apoptosis in NOD mice. 
In summary, our study demonstrates that the NOD T cell unique gene expression 
profile confers a deregulated stress response system, especially in the heat shock protein 
family, that may increase susceptibility of NOD T cells to apoptosis under various 
environmental stresses, which may result in lymphopenia. Our results implicate that 
clinical intervention to the components of the stress response system, especially heat 
shock family, such as Hsp90 or Hsp105, may pave a new way to diagnosis, prevents and 
treatment to type I diabetes. 
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 Part II: Comparison of gene expression profiles between human autoimmune diseases 
and murine models 
 
Introduction 
We have recently employed cDNA microarray techniques to screen gene 
expression profiles in human autoimmune disease and have found that each individual 
with one of four different autoimmune diseases shares a common profile (79).  A 
dominant feature of these profiles is the under-expression of key genes that encode 
proteins required for apoptosis, inhibition of cell cycle progression, and inhibition of cell 
differentiation and migration (79).  In general, critical genes that control biological 
processes are highly conserved among species. It has been argued that it is possible to 
identify these genes by comparing conserved biological processes among species.  
Therefore, we hypothesized that critical differentially expressed genes (DEGs) that may 
regulate autoimmune disease may be shared among human autoimmune diseases and 
murine models of spontaneous autoimmune disease.   
To address this question we used cDNA microarray analysis to compare gene 
expression profiles in resting T cells among two autoimmune strains, NOD and NZM, 
and a non-autoimmune strain, C57BL/6.  We asked two questions.  First, we compared 
gene expression profiles between the two murine autoimmune strains to determine if they, 
like human autoimmune disease, shared overlapping profiles of gene expression.  Second, 
we compared gene expression profiles in the murine models to the unique gene 
expression profiles observed in human autoimmune disease to identify genes that 
displayed common differential expression.  Our results show that there is very little 
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 overlap between gene expression profiles in T cells in human and murine autoimmune 
disease and between two different autoimmune murine models.  
 
Materials and methods 
Mice: NOD, NZM (2410), and C57BL/6 mice were obtained from Taconic 
(Germantown, NY 12526) and housed in the Vanderbilt University animal facilities.  
Female mice were used between 8-24 weeks of the age.  
Reagents: Complete RPMI 1640 medium supplemented with 10% FBS (Lot ALK 
14837; HyClone Laboratories, Logan, UT), 100 U/ml of penicillin, 100 μg/ml of 
streptomycin, 2mM L-glutamine, and 0.05 mM 2-ME (J. T. Baker, Phillipsburg, NJ) was 
used for cell culture. The mAbs used in this study were purified from tissue culture fluids 
of hybridoma cells obtained from American Type Culture Collection (Manassas, 
VA/Rockville, MD): anti-I-A (10-3.6.2, specific for I-A g7, k, r, f, or s haplotypes; Y3P, 
specific for I-A b, f, p, q, r, s, u and v haplotypes,).  BioMag® Goat anti-Mouse IgG 
coated magnetic beads were obtained from QIAGEN (Valencia, CA).  Tri Reagent was 
obtained from Molecular Research Center, INC.  Superscript II transcriptase was 
obtained from Invitrogen (Carlsbad, CA).  PCR purification kits were obtained from 
QIAGEN.  CMTTM hybridization chambers were obtained from CORNING (Corning, 
NY).  Cy5, Cy3 and other reagents used for cDNA labeling and hybridization were 
obtained from the Vanderbilt Microarray Shared Resource.  The Vanderbilt Microarray 
Shared Resource made NIA mouse 15K microarray chips.  
NIA Mouse 15K cDNA clone set: The NIA mouse 15K cDNA clone set is a 
15,247-element clone set. The 15K clone set was developed at the National Institutes of 
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 Aging (NIA) and has been sequence verified by sequencing from both the 5’ and 3’ 
termini.  Approximately 15,000 unique cDNA clones were derived from 52,374 ESTs 
from pre- and periimplantation embryos, E12.5 female gonad/mesonephros, and new 
born ovary (214).  Every cDNA clone is assigned a unique clone ID in the mouse 15K 
NIA clone set.  
CD3+ T cells purification: CD3+ T lymphocytes were purified from spleen by 
negative selection.  Red blood cells were removed by hypotonic lysis.  I-A expressing 
cells were incubated with anti-I-A mAb (10-3.6.2 for NOD, Y3P for NZM 2410 and 
C57BL/6) for 30 min at 0◦-4◦C.  Labeled cells were depleted by incubation with goat-anti-
mouse IgG coated magnetic beads at room temperature for 30 min.  Cells bound to beads 
were removed by a magnet column.  Average purity of CD3+ T cells was approximately 
90-95% as determined by flow cytometry.  
Total RNA isolation: Tri Reagent was used to isolate total RNA from splenic T 
cells according to the manufacture’s protocol.  We pooled total RNA from the T cells of 
2-3 mice for each microarray experiment.  This provided us with sufficient total RNA 
and decreased bias due to biological variation.  We used 5×107 cells to isolate total RNA 
for each group (experimental and control) for each microarray experiment.  
Labeling of cDNA: Labeled cDNA was prepared from 30 μg aliquots of total 
RNA. RNA was transcribed into fluorescently labeled cDNA using an anchored oligo-dT 
primer (dT20MN), unlabeled dNTPs, superscript II reverse transcriptase, and dCTP 
labeled with one of the two fluorophores, Cy5 or Cy3, according to the standard protocol 
of Vanderbilt Microarray Shared Resource.  Cy5 was used to label the experimental 
samples (NOD or NZM); Cy3 was used to label the control samples (C57BL/6).  The 
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 Cy5 and Cy3 labeled cDNAs were combined in Buffer PB and purified together by using 
the PCR purification kit. Finally, the combined samples were dissolved in 2x 
hybridization buffer (50% formamide, 10x SSC and 0.2% SDS). 
Microarray hybridization and data analysis: Microarrays were prehybridized in 
prehybridization solution (1% BSA, 5x SSC, and 0.1% SDS) at 55°C for 45 min.  After 
prehybridization, arrays were rinsed 5 X in MilliQ water, 1X in isopropanol, and allowed 
to air dry. Combined samples were placed on the prehybridized slide and covered with a 
lifterslip.  Microarrays were hybridized at 42°C for 14-16 hours in a humidified 
hybridization chamber.  After hybridization, the lifterslip was removed and the 
microarray slide was washed at room temperature with serial 5-min washes with 2x SSC, 
0.1%SDS, 1x SSC, and 0.1x SSC.  Microarray slides were dried by centrifugation at 50 x 
g for 5 min. Microarray slides were scanned using a GenePix® 4000B scanner (Axon 
Instrument Inc., Union City, CA). Image files were analyzed with GenePix® Pro 3.0 
software (Axon Instrument Inc., Union City, CA). The software package was used to 
identify individual clones from the microarray image and to calculate signal intensity 
values after normalization. Ratios (fluorescent intensity of experimental sample/ 
fluorescent intensity of control sample) from the two channels (red: Cy5, green: Cy3) 
represent the fold difference in gene expression levels between the two samples. Each 
microarray was performed at least in triplicate and results were averaged. 
Definition of DEGs: We arbitrarily defined a DEG as a gene or clone that 
exhibited a greater than 3-fold difference in expression between two samples with a P < 
0.05 (using the student's T test). 
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 Comparison of human and murine mice microarray data: To identify overlapping 
DEGs in mouse and human datasets, we used human clone accession numbers to search 
the GeneCardTM database (229) to identify corresponding human DEGs.  We used the 
same database to determine if there was a known homologous murine gene.  If so, we 
searched our mouse microarray dataset to find the corresponding genes.  Expression 
levels of the corresponding murine genes were obtained from microarray datasets.  If the 
gene was also a DEG in murine datasets and had the same expression pattern (under-
expressed or over-expressed) as that in the human microarray dataset, we called this gene 
an overlapping DEG between human autoimmune disease and the corresponding murine 
autoimmune disease model. 
Gamma irradiation induced apoptosis: T cells were purified from the murine 
strains: NOD, NZM and C57BL/6, and were cultured in complete RPMI 1640 media with 
L-glutamine (2mM), FCS (fetal calf serum 10%) and 2-ME (0.2mM) in 6-well plates at a 
concentration 1×106 cells/ml.  Cells were exposed to a total of 4 Gy of gamma irradiation 
using a Marker 1 Irradiator (J.L.Shepherd & Associates, Glendale, Calif.) at a dose rate 
of 1.897 Gy/min at room temperature.  Cell viability was calculated by determining live 
cell numbers after gamma irradiation to non-irradiated controls. 
 
Results 
 
Gene expression profiles in T cells from autoimmune NOD and NZM strains 
A striking feature of our microarray analyses of human autoimmune disease was 
that most DEGs were identical in each of four distinct autoimmune diseases, IDDM, SLE, 
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 RA, and MS(79).  Therefore, we wanted to determine if T cells from NOD and NZM 
strains shared common DEGs when compared to C57BL/6.  We used microarrays to 
compare gene expression profiles between autoimmune-prone NOD, NZM T cells and 
non-autoimmune C57BL/6 T cells.  First, we identified DEGs in the NOD versus 
C57BL/6 data set (Fig. 6-7 A).   
 
 
Figure 6-7. Comparison of gene expression profiles in NOD and NZM T cells.  A. NOD T cell 
DEGs were identified from our microarray data set.  The corresponding expression levels of these 
genes in NZM T cells are shown. B.  The reciprocal experiment shows NZM T cell DEGs and 
their corresponding expression levels in NOD T cells of NZM in NOD dataset. C. Overlapping 
DEGs between NOD and NZM data sets. 
 
 
Next we checked their expression levels in the NZM data set to determine if NOD DEGs 
were also NZM DEGs.  We performed the reciprocal analysis by identifying NZM DEGs 
and checking their expression level in the NOD data set. We found 59 DEGs in the NOD 
data set for which we could find corresponding expression data in NZM data set, and 172 
DEGs in NZM data set with corresponding expression data in the NOD data set. But, in 
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 contrast to the situation with different human autoimmune diseases, we only found three 
overlapping DEGs between the two autoimmune mouse models (Fig. 6-7 A, B and C). 
 
Comparison of DEGs between murine autoimmune models and human autoimmune 
disease 
 
 
From human public databases, we identified DEGs for each human autoimmune 
disease.  There was considerable overlap in expression levels among this set of genes in 
each human autoimmune disease (Fig. 6-8 A).  
 
 
 
Figure 6-8. Comparison of gene expression profiles between human autoimmune diseases and 
murine models of autoimmune disease.  A. Overlapping DEGs in four different human 
autoimmune diseases (IDDM, SLE, RA, MS). B. Expression profiles of human IDDM DEGs in 
NOD T cells. C. Expression profiles of human SLE DEGs in NZM T cells. D. Overlapping DEGs 
between the NZM mouse model and human SLE. E. Comparison of gamma irradiation induced 
cell death in NZM, NOD and B6 T cells.  
 
 
Next, we searched public databases (229) for the murine homologues and examined our 
microarray database to determine if we had expression data of a corresponding gene or 
clone.  We were able to identify 129 murine clones represented in our microarray dataset 
that were homologous to human autoimmune disease DEGs.  Next, we determined if 
these DEGs were also differentially expressed in T cells from NOD and NZM (Fig. 6-8 B 
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 & C).  When we compared human IDDM with NOD mouse data, we did not find any 
overlapping DEGs between human and mouse data sets.  We compared the DEGs in SLE 
to our NZM microarray data set and found two overlapping DEGs (Fig. 6-8 C & D). 
 
Gamma-irradiation induced apoptosis 
Analysis of DEGs in human autoimmune disease suggests that lymphocytes that 
have this gene expression signature should have defects in cell cycle control and 
apoptosis, especially p53-mediated damage response pathways (79). Gamma-irradiation 
induced cell death is known to be dependent upon p53.  Lymphocytes from individuals 
with human autoimmune disease express very low levels of basal TP53 mRNA and p53 
protein (79, 230).  They also fail to undergo gamma-irradiation induced cell death (230).  
Therefore, we wanted to determine if lymphocytes from autoimmune NOD and NZM 
(2410) strains also exhibited defects in gamma-irradiation induced cell death when 
compared to non-autoimmune strains.  T cells from NOD and NZM murine strains did 
not show noticeable resistance to gamma-irradiation induced apoptosis compared with 
non-autoimmune strains (Figure 6-8 E).  This result is consistent with our microarray data 
that demonstrated that expression levels of Trp53 were equivalent in T cells from 
autoimmune and non-autoimmune strains. 
 
Discussion 
We have found a conserved gene expression profile in the lymphocytes of humans 
with autoimmune disease.  This profile is also seen in unaffected first-degree relatives 
arguing that it arises, at least in part, from genetic factors rather than the disease process 
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 (79, 178). We had two goals in this study.  First, we wanted to determine the extent to 
which this conserved gene expression pattern was conserved in murine models of 
spontaneous autoimmune disease.  Second, we wanted to determine the extent to which 
strains with distinct autoimmune diseases shared common gene expression profiles.  We 
did not find overlapping DEGs in T cells between human autoimmune disease and NOD 
mice.  We only found 2 overlapping DEGs in T cells between human autoimmune 
disease and NZM 2410 mice, and we found 3 overlapping DEGs in T cells between NOD 
and NZM mice.  After gamma irradiation, a p53 dependent response, T cells from human 
autoimmune patients have strong resistance to gamma irradiation induced apoptosis (230) 
and T cells from murine autoimmune and non-autoimmune strains show similar 
sensitivity to gamma-irradiation induced cell death.  Therefore, these autoimmune models 
may not perfectly match their corresponding human autoimmune diseases.   
The NOD mice we used are at the age of 8-12 weeks old. We know that the NOD 
mouse exhibits autoimmune pancreatic insulitis at the age of four weeks (231) and 
insulin-dependent diabetes is seen in females as early as 12 weeks of age (142). Most 
female NOD mice at 20-24 weeks of age have elevated blood glucose levels. In fact, we 
compared gene expression profiles of different age NOD mice to determine if they 
change as the autoimmunity progresses from recognition of self-antigen to insulitis to 
diabetes. To do so, we performed microarray analysis of T cells from age-matched mice 
of 4-6 week, 8-12 week and 20-24 week of age. In this experiment, we did not observe 
differences in gene expression profiles between older and younger mice.  Most of the 
DEGs among three different age mice showed the same gene expression pattern.  These 
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 results suggest that differences in gene expression profiles in the total T cell population 
do not change dramatically during autoimmune disease progression. 
NZM (2410) mice develop glomerulonephritis by one year of age in ~80% of 
males and females. Anti-dsDNA IgG antibodies are also present in the sera of ~80% of 
animals by six months of age (61). The mice we used for our analysis were 8-15 weeks 
old. We do not exactly know if the gene expression profiles in NZM (2410) T cells will 
change with disease progression. However, based upon our studies in NOD T cells, it is 
reasonable to suspect that the gene expression profile in NZM (2410) T cells will not 
change with disease progression.  In addition, the gene expression profile observed in 
humans with autoimmune disease is also observed in unaffected first-degree relatives of 
affected individuals suggesting that this gene expression profile may not reflect disease 
activity. 
Since we did not find overlapping DEGs between human autoimmune diseases 
and their murine counterparts, we searched for murine DEGs that may confer a similar 
cellular phenotype.  In fact, our microarray data support this notion.  It has been 
described elsewhere that there are multiple apoptosis defects in animal models and 
human autoimmune diseases (232-235). Many gene expression differences in 
lymphocytes from human autoimmune disease patients predict defects in cell cycle 
control and apoptosis.  Although we did not see similar DEGs in cell cycle control and 
apoptosis in NOD T cells, we found that one gene, Ptpn13, which encodes the FAP-1 
protein, is over-expressed.  This protein inhibits Fas-mediated apoptosis (236-239).   
Therefore, these results may indicate that physiological defects in apoptosis are a 
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 common property of both human autoimmune disease and murine models of autoimmune 
disease.  
When we compared NZM data with SLE data, we found two overlapping DEGs.  
One was the down-regulated gene Cdkn1b, which encodes p27kip1 that is a cyclin-
dependent kinase inhibitor that is a regulator of cell cycle progression. p27kip1 is also an 
essential anergy factor for the blockade of clonal expansion of alloreactive human and 
mouse helper T lymphocytes through inhibiting interleukin 2 transcription (240).  And it 
is described elsewhere that p27kip1 is down regulated in an autoimmune disease- 
Hashimoto's thyroiditis (HT) and its down regulation is independent of the proliferative 
status and of changes in the proteins it regulates, Skp2 and cyclin D3 (241). p27kip1 also 
has a redundant function with p21 (242-244).  p21 is indispensable for maintaining 
tolerance and preventing a lupus-like syndrome in female mice, as p21 knockout mice 
develop severe lupus-like disease (157).  We do not have gene expression data from our 
NIA mouse 15K cDNA clone set or human microarray dataset for the gene that encodes 
p21 (Cdkn1a) but we do know that basal and inducible levels of p21 are depressed in 
lymphocytes from patients with autoimmune disease (79).  Taken together, it is likely 
that the defects in expression of both cyclin kinase inhibitors, p21 and p27, contribute to 
the pathogenesis of human autoimmune disease, including SLE, and lupus-related 
pathogenesis observed in the NZM model.  One major difference between the two species 
is that defects in the human can be linked to defects in the p53 damage response pathway 
while defects in the mouse occur in the presence of an intact p53 damage response 
pathway.  
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 In summary, our results show that there is not a significant overlap between DEGs 
in T cells from human autoimmune disease and murine models of autoimmune disease.  
In contrast to human autoimmune disease, there is also not significant overlap between 
DEGs from two distinct murine autoimmune diseases.  However, the overlap that does 
exist may suggest that defects in conserved pathways produce a functional liability that 
may contribute to development of autoimmune disease.  For example, defects in 
apoptosis are predicted from our analysis of human autoimmune disease and these have 
been confirmed experimentally (230). Our findings suggest that NOD T cells may also 
have a defect in apoptosis but this may arise from increased expression of an inhibitor of 
apoptosis, Ptpn13, rather than a defect in expression of a gene that is required for 
apoptosis.  Our analysis of NZM T cells shows a more direct parallel.  Defects in 
expression of cyclin kinase inhibitors are seen in T cells from both human autoimmune 
disease and murine models including SLE and NZM.  Other data indicate that these 
inhibitors of cell cycle progression are required to establish a state of tolerance or anergy 
and their absence leads to development of sex-linked lupus in mice (157).  
Our results indicate that murine models do not perfectly model their 
corresponding human autoimmune diseases when gene expression profiles are considered.  
Other investigators have previously recognized limitations of using rodent models to 
study human diseases. Failure of DNA vaccine technology in humans demonstrates that 
success in murine models does not necessarily translate to success in human trials.  Study 
of murine models has benefited our understanding of basic principles of immunology 
research. However, using one inbred, engineered species to study the diseases of outbred 
humans is a big limitation. It has been suggested that large animals may better model 
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 human diseases (245). There is relative agreement that type 1 diabetes in humans and 
spontaneous type 1 diabetes-like syndromes in animal models are autoimmune disorders. 
But, interventions to prevent diabetes based on mice research has not been successfully 
transferred to humans (246). Our results further confirmed that autoimmune murine 
models do not perfectly model their corresponding human autoimmune disease at least in 
the perspective of gene expression profile. But they do have some similar phenotypes that 
may result from conserved pathological pathways.  
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 CHAPTER VII 
 
GENERAL DISCUSSION AND CONCLUSION REMARKS 
 
Gene expression profiling with microarray can screen expression levels of 
thousands of genes simultaneously and help identify comprehensive molecular signatures 
of certain states of disease. Therefore, it is very powerful tool to study multigenic 
diseases, such autoimmune and atopic diseases. The work of this thesis tests the 
possibility of performing gene expression profiling using peripheral blood mononuclear 
cells (PBMC) as source to characterize diseases. The application of gene expression 
profiling can be basically divided into three objectives-classifying disease phenotypes, 
monitoring or predicting responses to treatment, and predicting disease outcome. In this 
chapter, I will use the following flowchart (Fig. 7-1) as a simplified outline to discuss the 
relevant points of this thesis and important implications of our work. 
 
PBMC GEP
Classifying
Responses 
to treatments
Prognosis
autoimmune diseases
allergic rhinitis
Response to immunotherapy
ERA future disease severity
Personalized 
medicine
Genetic factors
Environmental 
and other factors
 
Figure 7-1. Flow chart of from gene expression profiling to personalized medicine, GEP, 
gene expression profiling. 
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 Classifying disease types or subtypes is an objective of gene expression profiling. 
Previously, we identified a common gene expression profile that can distinguish 
individuals with autoimmune disease from the healthy control group (79). Unaffected 
first-degree relatives of individuals with autoimmune disease share a portion of this 
profile suggesting it is of genetic origin independent of disease onset (120). Therefore, 
genetic factors and other factors such as environmental factors and regulatory events may 
combine to establish this disease specific gene expression profile. In chapter III, we 
identified a common gene expression profile which distinguished a cohort of autoimmune 
individuals from both the healthy control group and the unaffected family member group, 
thus, this gene expression profile is common feature of autoimmune disease and is 
without influence of genetic components.  Gene expression profiles specific for a 
particular disease or a specific state of disease have also been demonstrated, such as the 
unique gene expression profile in MS (149) which can distinguish individuals with MS 
from healthy controls, and a unique gene expression profile in early RA (about one year 
disease duration) which can distinguish early RA from established RA (about 10 years 
disease duration). Recently, an interferon signature in SLE was identified by several 
groups (83, 89, 90, 247). The expression profile of these interferon signature genes seems 
specific for SLE and may be correlated with SLE disease activity (83), but is not a 
common gene expression profile for autoimmune disease as we identified in chapter III, 
and they can not be found in other autoimmune disease-RA (247).  
 The common autoimmune disease expression profile identified in chapter III is 
shared by individuals with both early RA (about one year disease duration) and 
established RA (about 10 years disease duration), this result implies that this common 
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 autoimmune diseases expression profile is acquired shortly after disease onset and is 
sustained independent of disease duration.  How this specific gene expression profile is 
maintained is not fully understood.  One possible explanation is that lymphocytes in 
blood are continuously exposed to cytokines as a result of the chronic inflammation and 
the unique gene expression signature is a product of cytokine stimulation.  In fact, 
expression of a unique gene expression signature in SLE is attributed to exposure to 
interferon (87, 88).  Our results do not rule out this possibility.  Presence of a common 
infectious agent could also explain this altered gene expression profile.  Exhaustive 
searches for infectious agents in autoimmune disease have failed to confirm this 
possibility.  However, our results do not rule it out either.  Somatic mutation of genomic 
DNA may cause a defect in some master transcriptional regulator resulting in variation of 
downstream gene expression levels.  This seems less likely since, unlike tumors, 
lymphocytes continuously die and are replenished in the periphery making it unlikely that 
a single or small number of somatic mutations could affect the majority of circulating 
lymphocytes.  Another mechanism of maintaining a specific gene expression profile may 
not involve DNA mutation, but rather alteration of gene transcription scaffold-chromatin 
structure under certain environmental conditions.  Examples include histone 
modifications or methylation of CpG DNA (248-250).  These epigenetic modifications 
have been tied to alterations in gene expression inherited by daughter cells.  Although it 
is generally thought that specific mechanisms sustain this memory or imprinting, these 
mechanisms are not clearly understood.  Nevertheless, our results provide a framework to 
permit more careful examination of the precise mechanisms involved in sustaining 
altered gene expression profiles in individuals with either autoimmune or atopic diseases. 
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 In parallel to gene expression profiling of PBMC in human autoimmune diseases, 
we also performed gene expression profiling in T cells of a human type I diabetes murine 
model- NOD (chapter VI). We identified NOD signature genes-NOD DEGs, which are 
differentially expressed, compared to B6 T cells. The most over-represented over-
expressed NOD DEGs are apoptosis inducing genes, and strikingly, almost all of the 
over-represented under-expressed genes are heat shock family genes including HSP90 
which is one of the most under-expressed genes in NOD T cells and is thought to be a 
master regulator of apoptosis (215-217, 223, 224) and may be involved in regulating T 
cell apoptosis (226, 227). Therefore, we postulate that NOD T cells may have a de-
regulated stress response system making NOD T cells more susceptible to apoptosis.  The 
difference in expression of NOD DEGs may result from the NOD specific host 
environment since the NOD mouse is progressing toward a diabetic status resulting from 
decreased insulin levels. Therefore, this complex environment may cause unknown 
effects on expression levels of certain genes such as heat shock family genes. However, 
the bone marrow transplantation experiments demonstrate that the differential expression 
pattern is independent of host environment, therefore, the differentially expressed NOD 
DEGs is rather an intrinsic trait than the result from NOD host environment. In fact, the 
in vitro cell culture experiments also support this idea, since in vitro cultured NOD T 
cells exhibit less resistance to gamma irradiation or heat shock induced apoptosis than 
that of B6 T cells cultured under the same conditions. Therefore, the NOD T cells are 
susceptible to apoptosis under environmental stress and it may cause lymphopenia in 
NOD mouse, and lymphopenia driven NOD T cells homeostatic proliferation may result 
in diabetes (17, 159, 160). When we compared the NOD signature genes and human 
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 autoimmune disease signature genes, we found very little overlap between differential 
gene expression profiles in T cells from NOD mouse disease and people with 
autoimmune disease. However, among the human autoimmune signature genes, BRCA1 
and TP53 are substantially underexpressed, this may also result in chronic lymphopenia 
in autoimmune individuals (chapter III, discussion), and similarly, lymphopenia may 
finally contribute to onset of autoimmunity in these patients. The NOD mouse and human 
autoimmune diseases do not have a common gene expression signature, but may have a 
common outcome resulting from these differentially expressed signature genes- 
lymphopenia, which may be a potential contributor to establishing autoimmunity.  
We have described a common gene expression profile of autoimmune disease in 
chapter III. We wanted to further test the possibility if we can use gene expression 
profiling to identify specific gene expression profiles in PBMC in another immune-
mediated disease-allergic rhinitis. In contrast to chapter III in which we identified a 
common signature for four autoimmune diseases, in chapter IV, we only examined a 
single atopic disease, allergic rhinitis. However, the expression profile of these signature 
genes in allergic rhinitis was completely distinguished from the healthy control group and 
the autoimmune disease group, indicating the presence of a unique signature in allergic 
rhinitis. Further work will have to be performed to identify the genetic and disease-
dependent portions of the atopic gene expression profile as we did in chapter III.   
Identifying the gene expression profile that can be used to monitor or predict 
individuals’ response to certain treatments is one of the objectives of gene expression 
profiling analysis. In allergic rhinitis, we demonstrated that gene expression profiling can 
be used to monitor responses to immunotherapy.  Key findings are that immunotherapy 
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 does not affect the entire signature gene expression profile for allergic rhinitis.  Rather, 
only a subset of genes alters expression levels after therapy. Nevertheless, these results 
demonstrate that the goal of using gene expression profiling in PBMC to monitor 
responses to therapies in human disease is feasible.   
In addition to classifying diseases and monitoring response to treatments, another 
objective of gene expression profiling is to predict disease course. With the assistance of 
supervised methods, we identified a gene expression signature in early RA capable of 
predicting future disease severity.  Although it was not possible to replicate these studies 
with a second population to validate our results, they suggest it may be possible to predict 
disease course with gene expression profiling in PBMC thus aiding the physician in the 
clinical management of their patients. To our knowledge, this is the first gene expression 
profiling study to identify prognostic factors in rheumatoid arthritis research (chapter V). 
One of the most important implications of our study is that using PBMC as the 
source to perform gene expression profiling to characterize diseases is feasible, even 
though the blood tissue is not the major site affected by the disease. Gene expression 
profiling has been performed with different tissue source; most of them are tissues of the 
major site where the diseases originate or directly affected by the diseases, such as 
microarray study in cancers using tissue samples at the site of the tumor (86, 102-104, 
108, 109); microarray studies in autoimmune diseases using kidney tissues of SLE (251), 
brain tissues of MS (81, 252), synovial tissues of RA (92, 93); microarray studies in 
atopic diseases using nasal tissues (96, 253, 254). Our results indicate that PBMC is a 
reliable source for gene expression profiling; even when PBMC are not the site that is 
directly affected by the diseases, such as the autoimmune diseases and atopic diseases. In 
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 fact, affected tissues used for microarray are generally only in small size that can not 
generate sufficient RNA for microarray study, and the positions to obtain the tissues may 
generate more variation compared to PBMC, because the changes of positions may result 
in variation of cell populations which can cause greater variations in microarray study.  In 
contrast, current protocols can generate enough RNA from PBMC and also the current 
protocol for isolating the PBMC from the whole blood can greatly decrease the 
contamination from other sources. Also, PBMC is a very easily accessible human tissue 
sample, as for patients, surgically removing a piece of affected tissues for microarray 
study may not be as easily accepted as collecting a tube of blood. However, PBMC as 
common source for diseases profiling needs further evaluation in other diseases such as 
certain cancers whose major affected sites are not blood. 
With the advance of technology, we can imagine that a tube of blood or even a 
drop of blood from patient can be used to extract comprehensive gene expression profiles, 
with referencing to the recorded phenotype signature profiles database for the diseases, 
we can determine individual’s disease phenotype, subtype, reveal the diseases 
progression, monitor the responses to different therapies, design novel personalized 
therapies or drugs, and evaluate the disease outcomes. Further, we can evaluate the 
liability of diseases in healthy individuals and help prevent the onset of disease. All of 
these will radically changed modern medicine: the prescriptions based upon individuals’ 
symptoms will be changed to be based upon personal genomic information; the clinical 
treatments will be changed to be tailored to pre-clinical prevention. This personalized 
medicine will revolutionize modern medicine and advance human health care to a bright 
new age. 
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